SYMPTOMS IN EARLY AND LONG-TERM BREAST CANCER SURVIVORS WHO HAVE COMPLETED PRIMARY THERAPY by Strunk, Faith
Texas Medical Center Library
DigitalCommons@The Texas Medical Center
UT SON Dissertations (Open Access) School of Nursing
12-2013
SYMPTOMS IN EARLY AND LONG-TERM
BREAST CANCER SURVIVORS WHO HAVE
COMPLETED PRIMARY THERAPY
Faith Strunk
UTHealth School of Nursing, fastrunk@pobox.com
Follow this and additional works at: http://digitalcommons.library.tmc.edu/uthson_etd
Part of the Nursing Commons
This is brought to you for free and open access by the School of Nursing at
DigitalCommons@The Texas Medical Center. It has been accepted for
inclusion in UT SON Dissertations (Open Access) by an authorized
administrator of DigitalCommons@The Texas Medical Center. For more
information, please contact laurel.sanders@library.tmc.edu.
Recommended Citation
Strunk, Faith, "SYMPTOMS IN EARLY AND LONG-TERM BREAST CANCER SURVIVORS WHO HAVE COMPLETED
PRIMARY THERAPY" (2013). UT SON Dissertations (Open Access). Paper 4.
SYMPTOMS IN EARLY AND LONG-TERM BREAST CANCER SURVIVORS 
WHO HAVE COMPLETED PRIMARY THERAPY 
A DISSERTATION 
SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN NURSING 
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON 
SCHOOL OF NURSING 
BY 
FAITH STRUNK MSN, FNP-BC, AOCNP 
DECEMBER, 2013 
Approval Form D-3 
The University of Texas Health Science Center at Houston 
School of Nursing 
Houston, Texas 
To the Dean for the School of Nursing: 
'\ 
I am submitting a dissertation written by Faith Strunk and entitled "Symptoms in 
Early and Long Term Breast Cancer Survivors Who Have Completed Primary 
Therapy." I have examined the final copy of this dissertation for form and content 
and recommend that it be accepted in partial fulfillment of the requirements for 
the degree of Doctor of Philosophy in Nursing. 
We have read this dissertation 
and recommend its acceptance: 
~~~~ 




rP Jkw i htk J_ 
Dean for the School of Nursing 
TABLE OF CONTENTS 
APPROVAL PAGE .......................... .. .. .... ... .... ... ..... ...... .. ...... ..... .. .... .. ii 
ACKNOWLEDGEMENTS (Optional).. ........... ...... .. ....... ... ............ ..... . iii 
ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iv 
SUMMARY OF STUDY.......... ..... .. .. ........ ... ... ... ... .... .. ... ... ..... ....... ... .. . 1 
PROPOSAL .... .... ........ ..... ... ....... ... ... .... .......... ....... .......................... ... 5 
Specific Aims ..... ... ......... .......... ....... .. ...................... .. ......................... 5 
Background and Significance ... ........... .... .. .... ... .. ...... ... ... ....... ..... .... ... 7 
Research Design and Methods . .. . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . .. . . . . . .. . . . . . . . . . . .. . . . 11 
Protection of Human Subjects .. . . . . .. . . . .. . .. . .. . . . . . . . .. . .. . ..... .. .. . . . . .. .. . . .. . . . . .. 17 
Women and Minorities Inclusion ... ...... .. ... ... .. ....... ....... ... ............ .... ... 18 
Literature Cited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 
MANUSCRIPT.... ... .... .... ... ...... ...... ..... ... ....... ........ ........................... .. . 24 
A A Cross-Sectional Assessment of Symptoms in Early- and Long-term 
Breast Cancer Survivors 
APPENDIXES 
A M. D. Anderson Institutional Review Board Approval letter ..... 56 
B UT Centralized IRB Review form ... ...... .. ..... .. ..... ....... .. ... . 59 
C CPHS IRB UTHSC confirmation letter......... ... ... ............. 62 
D Letter of support. ...... ... .... ..... ..... ... . . . . . . . . . . . . . . . . . . . . . . . . 64 
E Demographic/health history form ... ..... ........ .... ....... ....... .. 66 
F M. D. Anderson Symptom Inventory ...................... ...... ... 68 
G Karnofsky Performance Status................. .. ..... ........... .. ... 71 
H Charlson Comorbidity Index................... .. ... ..... .. .. .. .. .. .... . 73 
Subject log . . . . . . . . . . . . .. . . . . . .. . .. . . . . .. . .. . .. . . .. . . . . .. . .. . . . . . . . . . . . . . . . .. . . . . 75 
J Subject log by stage..... .. .......... ........ .... ... ........................ 77 
K Recruitment schedule... ..... ... ... ............ ... .. ..... ... .. ... ... .. ..... 79 
L Certificate of human subjects protection training .. . . . . . . .. . . . 81 
M Permission to use the Charlson Comorbidity Index ... . . .. . . 84 
N Permission to use the MDASI.... .. . .. . .. . .. . .. . .. . . . . . . . . . . .. .. . . . . .. . . 86 
0 TheM. D. Anderson Cancer Center Protocol 2012-0909... 89 
P Curriculum Vitae.... .... ................ .. ................ .... ......... 109 
t 
ACKNOWLEDGEMENTS 
I would like to thank: 
Dean Starck and M. D. Anderson Cancer Center for allowing me the opportunity 
to attend the accelerated doctoral program as the M. D. Anderson Scholar for the 
University of Texas Health Science Center at Houston School of Nursing 
Accelerated Doctoral Program. 
Dr. LoBiondo Wood for her guidance and perseverance. 
Dr. Armstrong and Dr. Theriault for their patience and encouragement. 
Dr. Linda Brown, who helped me deal with Mac to Windows issues, especially 
with references and with APA format questions. 
For the APN group in the Department of Breast Medical Oncology and especially 
Betty Harris, for their support. 
The statisticians- Bryan Fellman and Diana Urbauer- who were my lifelines for 
statistics. 
Kelly Brassil, who helped me with editing and was so supportive. 
Ruben Serna, Gil Guerra and the BMO research nurses who took me under their 
wing. 
LaTonia Okadigwe, who was instrumental in helping me with both the research 
protocol and getting the dissertation finalized (and in the correct format) . 
Deborah Erdmann and Cynthia Griffin without whose help I'd never have gotten a 
table in the correct format. .. or anything numbered correctly. 
To my husband and daughter, who agreed to my beginning the doctoral program, 
without knowing what they were in for, and having continued to support me 
throughout. 
To my mom, who was proud of me, and told everyone in her small town. 
To my church family, whose prayers helped sustain me. 
Special thanks go to the patients, nurses, physicians, and staff of the Nellie B. 
Connally Breast Center and the Breast Medical Oncology Department for their 
willingness to participate and support my research. 
iii 
Abstract 
Faith A. Strunk, MSN, FNP-BC, AOCNP 
Symptoms in Early and Long-Term Breast Cancer Survivors 
Who Have Completed Primary Therapy 
December 2013 
Background: 
Many breast cancer survivors continue to have single or multiple symptoms after 
they have completed primary cancer therapy. The quantifiable, subjective 
experience of multiple symptoms and their impact is defined as symptom burden. 
Previous research has focused on symptoms during primary therapy or shortly 
after completion. 
Objective: 
The objectives of this study were to determine whether symptom burden differed 
between survivor status (early/long-term) and/or endocrine or hormonal adjuvant 
therapy use. We hypothesized that there would be no difference in the symptoms 
expressed between early and long-term survivors. 
Methods: 
In this cross-sectional study, data were collected on 133 survivors, using theM. 
D. Anderson Symptom Inventory, Karnofsky Performance Status, Charlson 




Patients who were prescribed endocrine or hormonal therapy had higher 
symptom severity scores than those women who did not receive these therapies. 
There were no differences in symptom burden and symptom interference 
between early- and long-term survivors, and whether or not they took adjuvant 
therapy. As functional status increased, the patients' symptoms scores 
decreased. Comorbidities did not impact the symptom scores. 
Conclusions: Breast cancer survivors, both early and long-term, continue to 
experience symptoms, but those taking hormonal or endocrine therapy 
experienced higher symptom severity. Understanding the connections in early 
and late survivorship between symptoms, cancer therapy, comorbidities and 
functional status may result in improved symptom management and outcomes 
for breast cancer survivors. 
KeyWords: 
Breast cancer, survivor, symptoms, symptom burden, symptom interference, 
M.D. Anderson Symptom Inventory (MDASI), Karnofsky Performance Scale 
(KPS), Charlson Comorbidity Index (CCI) 
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Summary of the Study 
This dissertation consists of the dissertation proposal which includes the 
specific aims, background and significance, research design and methods, 
research subject risk and protection, literature cited and appendixes, in the 
format of a Public Health Service Grant (PHS 398) and a manuscript entitled 
"Symptoms in Early and Long-term Breast Cancer Survivors Who Have 
Completed Primary Therapy" which presents the primary findings of the current 
research study. The study was approved by the University of Texas M. D. 
Anderson Cancer Center Institutional Review Board (IRB) (Appendix A) the 
Institutional Review Board at the University of Texas Health Science Center at 
Houston and the Committee for the Protection of Human Subjects, (Appendix B, 
Appendix C). 
The overall objective of this research was to identify and compare the 
symptoms experienced by early (less than 3 years post completion of primary 
therapy) and long-term (3 through 5 years post completion of primary therapy) 
breast cancer survivors based on whether or not they are taking adjuvant 
hormonal or endocrine therapy. This study also explored the associations 
between functional status, symptom burden and comorbidities as assessed by 
the Karnofsky Performance Status (KPS) (Appendix G), theM. D. Anderson 
Symptom Inventory (MDASI) (Appendix F), and the Charlson Comorbidity Index 
(CCI) (Appendix H). 
The study was conducted in the Nellie B. Connally Breast Center at the 
University of Texas M. D. Anderson Cancer Center. One hundred thirty four 
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participants were recruited, signed informed consent, and completed the study 
forms; one later withdrew consent. 
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Descriptive statistics were used to assess the distributional characteristics 
and demographics across survivor status and hormonal therapy use. Symptom 
burden and interference were calculated . Chi-square, Fisher's exact test and t-
test were conducted to evaluate whether the characteristics differed by survivor 
status or use of adjuvant hormonal or endocrine therapy. A 2-way ANOVA was 
conducted to evaluate differences in symptom burden, symptom interference and 
burden/interference of individual symptoms. 
Eligible patients were identified from daily reviews of 28 clinicians' clinic 
schedules and were scheduled on the research recruitment schedule (Appendix 
K). To facilitate the recruitment process the following techniques were used: 
visiting all clinicians that had eligible patients at the start of each clinic day and 
alerting them which specific patients at which times were eligible for the study, 
then revisiting several times during the day to provide a reminder. In addition, 
each clinician's clinic nurse was notified of the potential participant(s) and 
requested to let the investigator know when this patient was seen. To address 
the space constraint issues, the investigator arrived before clinic hours started, to 
request a room in which to administer the questionnaires, as the clinicians were 
concerned with maintaining patient schedules. 
In order to track time from primary treatment, receipt of endocrine or 
hormonal therapy, and stage of disease to ensure equitable distribution of 
participant population, the investigator developed a subject log by stage form 
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(Appendix J). Patients were stratified by months post treatment; 0-36 months and 
37-60 months, for clarity, rather than less than 3 years and 3-6 years. 
A minor change to the protocol procedure was made for clarification of 
completion of the demographic history form , allowing the investigator or 
participant to complete it rather than participant only. 
An additional three participants were planned to be recruited because two 
recruited earlier were actually early rather than long-term survivors and one 
participant withdrew consent after completing the forms. All but one planned type 
of participant was recruited; the investigator was unable to recruit one stage Ill, 
long-term survivor not on adjuvant hormonal or endocrine therapy. A total of 134 
participants were recruited and the data from 133 analyzed. 
The primary findings of the research study are presented in the 
manuscript "Symptoms in Early and Long-term Breast Cancer Survivors Who 
Have Completed Primary Therapy" (Manuscript A). Demographic and clinical 
characteristics were well balanced between survivor status and adjuvant therapy, 
by design. There was no difference in symptoms between early and long-term 
survivors, although those on adjuvant hormonal or endocrine therapy had higher 
symptom severity. 
The appendixes A-P contain the following materials: theM. D. Anderson 
Institutional Review Board Approval letter, the UT Centralized IRB Review form, 
The Committee for the Protection of Human Subjects, the Institutional Review 
Board at the University ofT exas Health Science Center confirmation letter for 
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agreement to rely on MDACC reviewing IRB, the letter of support from the 
Department of Breast Medical Oncology chairman, the demographic data 
collection form, theM. D. Anderson Symptom Inventory, the Karnofsky 
Performance Status, the Charlson Comorbidity Index, the documents developed 
and used in the collection of data, (subject log, subject log by stage, recruitment 
schedule), certificate of human subjects protection training, permission to use the 
Charlson Comorbidity Index, permission to use the MDASI, theM. D. Anderson 




Breast cancer is the most common cancer in women in the United States, 
with approximately 2.9 million survivors as of February 2013 (American Cancer 
Society, 2013). Usual treatment for women with invasive breast cancer includes 
chemotherapy and/or biotherapy, surgery, and/or radiation followed by adjuvant 
hormonal therapy, if hormone receptor positive disease. 
The cancer and/or its treatment often cause multiple symptoms in 
survivors. These symptoms may also be related to other noncancer comorbidities, 
noncancer related medications or even other symptoms (Barsevick, Dudley, Beck, 
& Whitmer, 2005; Honea, Brant, & Beck, 2007; Kenefick, 2006). Symptoms may 
persist and can lead to reducing the dose or discontinuing treatment early which 
may affect long term survival (Bonadonna et al. , 2005; Bonadonna, Valagussa, 
Moliternia, Zambetti , & Brambilla, 1995; Cleeland, 2007). Persistent symptoms 
also affect the survivors' quality of life. 
Understanding the connections between symptoms, cancer therapy, 
comorbidities and functional status may result in improved symptom management 
and outcomes for breast cancer survivors. This study will evaluate the impact of 
functional status, cancer therapy, and comorbidities on the symptoms expressed 
in early (up to 3 years) and long- term (years 3 through 5) breast cancer survivors, 
who have completed primary therapy (surgery, chemotherapy or biotherapy, with 
or without radiation) and compare the symptoms between those taking hormonal 
therapy and those not taking hormonal therapy. 
Historically, the literature has addressed the survivors' symptoms during 
their primary therapy or shortly thereafter. But no studies have identified and 
compared the symptoms experienced by early and longer term breast cancer 
survivors based on whether or not they are taking adjuvant hormonal therapy. 
This study will identify symptoms that continue to be a problem in survivors who 
have completed primary therapy. This proposed study is significant because 
establishing this baseline will help to develop and pilot interventions that can be 
tested and used effectively in this population. 
Primary objectives. 
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1. To determine whether symptom burden differs between early 
survivors (less than 3 years post-primary therapy) and long-
term survivors (3 to less than 6 years post-therapy, 
inclusive) . 
2. To determine whether symptom burden differs between 
women who take endocrine or hormonal adjuvant therapy 
and those who do not. 
Secondary objectives. 
1. To determine, whether the effect of time post-treatment and 
endocrine or hormonal adjuvant therapy has an additive 
effect upon symptom burden or whether it has a synergistic 
or antagonistic effect upon symptom burden. 
2. To determine whether symptom interference differs between 
early survivors and long-term survivors and between those 
who do and do not take adjuvant endocrine or hormonal 
therapy, as well as to determine if time post-treatment and 
use of adjuvant endocrine or hormonal therapy have an 
additive or interactive effect upon symptom interference. 
3. To determine if differences in individual symptom severity 
and interference exist between early and long-term 
survivors, with and without the use of adjuvant endocrine or 
hormonal therapy. 
Exploratory objective. 
To determine whether functional status and comorbidities 
affect symptom severity and interference. 
Background and Significance 
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Breast cancer is the most common cancer in women in the United States 
(excluding skin cancer); 1 in 8 women will develop it during her lifetime 
(American Cancer Society, 2013). Overall women treated for breast cancer have 
an 89% survival rate after 5 years and 75% after 15 years with an estimated 2.9 
million breast cancer survivors in the United States as of February 2013 
(American Cancer Society, 2013). The number of all cancer survivors is 
projected to grow by 3% per year (Maddams et al. , 2009). The breast cancer 
population is no exception; due to improvements in cancer care, earlier diagnosis 
and treatment larger numbers of women are living longer and cancer-free after 
diagnosis and treatment. Many survivors, once having completed primary 
therapy (surgery, chemotherapy/biotherapy, and/or radiation) continue to have 
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long-lasting symptoms, single or multiple (Barsevick, 2007; Cleeland, 2007; Janz 
et al. , 2007; Rosedale & Fu , 2010). The experience of multiple symptoms has 
been identified as symptom burden (Burkett & Cleeland, 2007; Gapstur, 2007; 
Gill, Chakraborty & Selby, 2012). Symptom burden is defined as the subjective, 
quantifiable prevalence, frequency and severity of symptoms and encompasses 
the patient's perception of the impact of symptoms (Cieeland , 2007; Gapstur, 
2007). 
The experience of symptoms in survivors has been evaluated , but much of 
the literature has been focused on symptoms and supportive care during primary 
therapy (Chung, Cimprich, Janz, & Mills-Wisneski , 2009). Some studies have 
concentrated on the early survivorship periods; beginning at the end of primary 
therapy up until 27 months after completing primary therapy (Brant et al. , 2011 ; 
Ganz, Kwan , Stanton, Bower, & Belin, 2011 ; Janz et al. , 2007; Park, Bae, Jung, 
& Kim, 2011 ; Penttinen et al. , 201 0; Thompson, 2007; Yi, Swartz & Reyes-
Gibby, 2011 ). These studies have found symptoms related to primary therapy 
with an impaired quality of life related to these reported symptoms (Bower, 2009; 
Dahl, Nesvold , Reinertsen, & Fossa, 2011; Janz et al. , 2007; Park et al. , 2011). 
The symptoms most frequently cited in the aforementioned studies included pain, 
fatigue or lack of energy, difficulty sleeping, arm pain and lymphedema, breast 
symptoms, feeling irritable or nervous, menopausal symptoms, weight changes, 
nausea, depression, and cognitive dysfunction. A number of studies have 
focused on a specific symptom, such as pain (Lundstedt et al. , 2012; Mao et al. , 
2009; Rief, Bardwell, & Dimsdaile, 2011 ) , lymphedema (Armer & Stewart, 201 0; 
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Meeske et al. , 2009; Smoot et al., 201 0), fatigue (Bower et al , 2008; Bower, 
Ganz, Irwin, Arevalo, & Cole, 2011; Thompson , 2007) or menopausal symptoms 
(Leining et al., 2006; Loibl, Lintermans, Dieudonne, & Neven, 2011 ; Ruddy et al. , 
2011). Cancer related fatigue was identified by 21% of both the 1-5 year and 5-
10 year survivors (Bower et al. , 2008). Sleep disturbances, fatigue and pain 
persisted in Hartl et al.'s (2003) study of survivors evaluated at an average of 4.2 
years. 
Several studies have had contradictory findings. Castellon et al. (2004) 
found that cognitive dysfunction symptomatically abated in the 12-24 months 
after adjuvant chemotherapy. Jim et al. (2009) found significant differences in 
cognitive functioning and cognitive impairment between women who had 
received chemotherapy or radiation compared to healthy matched controls after 
6 months. In a 2004 review, Tannock, Ahles, Ganz and van Dann found durable 
cognitive effects in 9 to 75% of patients, although the higher percentages were 
seen in those evaluated in a closer time frame with chemotherapy. However, in 
their study of longer term survivors (5- 15 years), Klein et al. (2011) found an 
improvement in all symptoms except cognitive functioning and insomnia. The 
discrepancies among the findings may be related to the variability in primary 
therapy over time, pre-existing comorbidities or the use of adjuvant endocrine or 
hormonal therapy. 
The proposed study will address the symptoms experienced by both early 
survivors (less than 3 years after completion of primary therapy) and long-term 
survivors (years 3-5 after completion of primary therapy). Symptoms may be 
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caused by comorbid illnesses or acute injuries, related to the disease itself or 
may be caused by treatments, in which case they are called side effects or 
toxicities (Cieeland , 2007). The framework of Symptom Burden (Cieeland, 2007; 
Gapstur, 2007) is the conceptual framework chosen for this study. Symptom 
burden has been described as the subjective counterpart to tumor burden 
(Cieeland & Reyes-Gibby, 2002) as well as the sum of the severity and impact of 
symptoms (Cieeland , 2007). It affects multiple patient outcomes, including 
survival, functional status and quality of life (Gapstur, 2007). Symptom burden is 
active, and changes over time, as patients undergo therapy or experience 
exacerbations or remissions of their disease (Vig & Pearlman, 2003). In this 
framework, symptoms related to therapy often are viewed as complicating post 
treatment recovery (Cieeland, 2007; Cleeland & Reyes-Gibby, 2002). 
In this study, we will assess functional status, comorbidities and the 
experience of symptom burden. This study also will explore the association of 
comorbidities and symptoms expressed by early and long-term survivors. The 
evaluation of concurrent comorbidities is warranted because comorbidities have 
been related to symptom severity (Kurtz, Kurtz, Stommel, Given, & Given, 1999). 
This study will also address the associations between functional status and 
symptoms related to adjuvant endocrine or hormonal therapy. 
Historically, the literature has addressed the symptoms of survivors during 
their primary therapy or shortly thereafter. But no studies have identified and 
compared the symptoms experienced by early and long-term breast cancer 
survivors related to the use of adjuvant endocrine or hormonal therapy. 
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Innovation 
This study is innovative in that it will identify symptoms that potentially 
continue to be a problem for survivors who have completed primary therapy. This 
study will compare symptoms experienced among women taking adjuvant 
endocrine or hormonal therapy and those not taking endocrine or hormonal 
therapy, in early (less than 3 years after completion of primary therapy) and long-
term (years 3 through completion of year 5 post primary therapy). 
Research Design and Methods 
Design. 
This study utilized an exploratory cross-sectional study design. 
Sample and setting. 
The sample for this cross-sectional design study will be drawn from adult 
female patients in the Nellie B. Connally Breast Center at the University of Texas 
M. D. Anderson Cancer Center, an academic, comprehensive cancer center. M. 
D. Anderson is the largest institution in the University of Texas system, with 631 
inpatient beds and 1,281,489 outpatient visits in 2012. The Nellie B. Connally 
Breast Center served over 4,720 new patients and consultations with over 33,000 
follow-up visits in 2012. Non-English speaking women will be recruited through 
appropriate translation with the assistance of the language assistance office. 
Potential participants will be approached at the time of their scheduled routine 
clinic visit after approval by their clinic physician. One hundred twenty eight 
participants will be recruited ; 64 for each arm. 
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Study participants must be an adult female survivor of invasive breast cancer, 
without clinical evidence of disease and have completed primary therapy (surgery, 
chemotherapy/biotherapy, and radiation). She may be continuing adjuvant 
hormonal therapy. She may be non-English speaking. Participants may not be 
diagnosed with noninvasive, metastatic, inflammatory, or recurrent breast cancer 
and may not be currently receiving chemotherapy or biotherapy. We plan to enroll 
33 early survivors who have not received adjuvant endocrine or hormonal therapy, 
33 early survivors who have received (or are currently receiving) adjuvant 
endocrine or hormonal therapy, 33 long-term survivors who have not received 
adjuvant endocrine or hormonal therapy, and 33 long-term survivors who have 
received (or are currently receiving) adjuvant endocrine or hormonal therapy. We 
will stratify the participants by stage so that 1/3 of each group will have had Stage 
I cancer, 1/3 will have had Stage II cancer and 1/3 will have had Stage Ill cancer. 
We expect that approximately 80% of breast cancer patients will have used 
adjuvant endocrine or hormonal therapy, and that the pool of early-term survivors 
will be larger than the pool of late-term survivors. 
Instruments. 
M. D. Anderson Symptom Inventory (MDASI) . The MDASI is "a 
brief measure of the severity and impact of cancer- related symptoms" 
(Cieeland et al. , 2000, p.1634) over the previous 24 hours and is 
completed by the breast cancer survivor. It contains 13 core symptoms: 
fatigue, sleep disturbance, pain , drowsiness, poor appetite, nausea, 
vomiting shortness of breath, numbness, difficulty remembering, dry mouth, 
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distress and sadness using a 0 (not present)-10 (as bad as you can 
imagine) numerical rating scale. Six additional items describe how much 
the symptoms have interfered with the patient's life during the past 24 
hours using a 0 (did not interfere)- 10 (interfered completely) numerical 
scale: general activity, mood, work (including work around the house}, 
relations with other people, walking and enjoyment of life. The patient 
completes the MDASI over 5-7 minutes. The MDASI has demonstrated 
internal consistency (reliability) with a coefficient alpha of 0.82 and validity 
established with factor analysis in many different studies (Paice, 2004). 
The MDASI has been psychometrically and linguistically validated in nine 
languages and linguistically validated in another 14 in addition to English. 
The MDASI will be used to evaluate symptoms over the previous week, 
rather than 24 hours. (Appendix F) 
Karnofsky Performance Status (KPS). The KPS is a clinician-
completed scale. It allows patients to be classified based on their degree of 
functional impairment, with a scale from 0 (dead) to 100 (normal, no 
complaints, no evidence of disease) (Schag, Heinrich, & Ganz, 1984). It is 
further subgrouped into three groups: 
A. Able to carry on normal activity and to work no special care is needed 
(80-1 00), 
B. Unable to work. Able to live at home, care for most personal needs. A 
varying degree of assistance is needed (50-70) 
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C. Unable to care for self. Requires equivalence of institutional or hospital 
care. Disease may be progressing rapidly (0 to 40). 
In this study, the KPS will measure functional status. The KPS has shown 
reliability and validity previously with Cronbach's alpha of .97 and construct 
validity demonstrated with a p<0.001 (Mor, Laliberte, Morris, & Wiemann, 
1984; Schag et al., 1984.) (Appendix G). 
The Charlson Comorbidity Index (CCI) . The CCI will measure 
comorbidities. The CCI is an investigator completed index that measures 
17 clinical conditions that are weighted to assess the effect of the 
conditions on the patient's prognosis (Charlson, Pompei, Ales, & 
MacKenzie, 1987). Item scores range from 1 to 6 for each item and are 
based on the relative risk for each. Scores range from 0 to 34, with higher 
scores signifying greater comorbidity. An adjustment will be made to 
address all participants beginning with a score of 2, given because they all 
have cancer. It has established reliability with clinical conditions, including 
cancer (Hall , Ramachandran, Narayan, Jani, & Vijayakumar, 2004) 
(Appendix H). 
Demographic/health history questionnaire. The demographic 
questionnaire includes age, educational status, race/ethnicity, primary 
language spoken, menstrual status (premenopausal- still having periods, 
perimenopausal- usual pattern of periods is altered , and postmenopausal-
no periods for one year or more), work status (employed or not), co-
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morbidities (Have you been diagnosed by a health care provider with any 
chronic medical condition- if so please list. If yes, has this condition limited 
your current daily activities?) (Appendix E). Treatment history was obtained 
from the medical record by the investigator (date and type of surgery 
(segmental mastectomy vs. mastectomy), type of lymph node surgery if 
any,(sentinel node biopsy or axillary node dissection), 
chemotherapy/biotherapy (anthracycline, taxane, non-anthracycline and/or 
trastuzumab), radiation, and adjuvant hormonal treatments (tamoxifen, 
toremifene or aromatase inhibitors). 
Data Collection Procedures. 
Study participants will be identified, consented and enrolled at the time of 
routine follow-up outpatient clinic visit to the Nellie B. Connally Breast Center. The 
health history/demographic questionnaire and the MDASI will be completed by the 
participant once enrolled . Data collection will take approximately 10 - 15 minutes. 
The principal investigator will determine the Karnofsky score and review the 
treatment history from the electronic medical record. 
Analysis. 
Assuming that 64 patients are enrolled in each arm, we will have 80% 
power to detect a difference of medium effect size equivalent to half a standard 
deviation in a 5% significance test for acceptable levels of type one and type two 
error. Descriptive statistics will be used to assess the distributional 
characteristics and demographics across survivor status and hormonal therapy 
use. Symptom burden and interference will be calculated separately, as 
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recommended by the MDASI User Guide. Chi-squared , Fisher's exact test and t-
test will be conducted to evaluate whether the characteristics differed by survivor 
status or use of adjuvant hormonal or endocrine therapy. A 2-way ANOVA will be 
conducted to evaluate differences in symptom burden, symptom interference and 
burden/interference of individual symptoms. Finally, we will add Karnofsky 
Performance Status and the Charlson Comorbidity Index to our models to 
evaluate impact of functional status and comorbidities upon symptoms. All 
models will contain terms for stage of disease to account for stratification on that 
factor, as well as a term for age to adjust for the effects of age upon symptom 
severity and interference. 
Limitations. 
There are several potential limitations. Participants will be recruited from 
the Nellie B. Connally Breast Center, while there for a routine visit, and therefore 
will not be randomly selected. Inclusion will be dependent on the participants' 
willingness to participate. Previous studies in this facility have been conducted 
with primarily Caucasian, middle class, well-educated participants and may not be 
generalizable to minorities or other groups. Because this study is performed at 
one Cancer Center, the results may not be generalizable to other patients in other 
centers. 
A pilot study will precede the planned dissertation research study and will 
allow the researcher to identify study limitations and problems, in order to address 
them. Even with these possible limitations, this study will provide new information 




An alternative approach to studying the identified variables would be a 
prospective longitudinal study, The use of a cross-sectional design was chosen 
because of the need to gather preliminary data; a later longitudinal cohort study is 
planned to evaluate the symptoms in a cohort beginning at 1 year post diagnosis 
through 5 years, to evaluate which symptoms persist throughout the 5 years. 
Protection of Human Subjects 
All consenting members of the research team will undergo institutional 
review board training as required by the University of Texas M. D. Anderson 
Cancer Center including a 4 hour institutional course and a 1-hour electronic IRB 
review module required by the University of Texas MD Anderson Cancer Center 
The Institutional Review Board at The University of Texas MD Anderson Cancer 
Center will review and approve all consenting materials, including the attached 
draft of the informed consent template, prior to use in consenting study 
participants. Reciprocal approval will be obtained from the University of Texas 
Health Science Center at Houston Committee for the Protection of Human 
Subjects 
Potential study subjects will be consented at the time of the routine follow 
up visit. Risks associated with participation in the study will be outlined in the 
informed consent and reviewed with potential subjects by the consenting member 
of the research team. Potential participants will be reassured that non-
participation will not impact their care. Potential risks of study participation are 
minimal as the study will consist of completion of questionnaires and data 
collection from the medical record. 
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Consent documents, in addition to study data will be maintained in a locked 
file in the Principal Investigator's office and any electronic templates will be 
password protected on an institutional computer. Finally, continual oversight for 
the ethical procedures of the proposed study will be provided by the institutional 
IRB in the form of spontaneous auditing of consenting and data collection 
materials. 
Women and Minorities Inclusion 
All female adult breast cancer survivors attending a follow up visit to the 
Nellie B. Connally Breast Center will be approached to participate in this study. 
The racial composition of this patient cohort includes individuals of predominantly 
Caucasian, middle eastern and Hispanic descent. Non-English speaking 
survivors will be approached through the use of a translator in order to broaden 
the inclusion of minorities. Women and minority patients are recipients of breast 
cancer treatment and as such will be invited to participate in the study and 
included to the degree which they consent to participate. 
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Many breast cancer survivors continue to have single or multiple symptoms after 
they have completed primary cancer therapy. The quantifiable, subjective 
experience of multiple symptoms and their impact is defined as symptom burden. 
Previous research has focused on symptoms during primary therapy or shortly 
after completion of treatment. 
Objectives 
Our study objectives were to determine whether symptom burden differed 
according to survivor status (early as opposed to long-term survival) and/or use 
of endocrine or hormonal adjuvant therapy. We hypothesized that there would be 
no difference in the symptoms expressed among early- and long-term survivors. 
Methods 
In this cross-sectional study, data were collected on 133 survivors, using the MD 
Anderson Symptom Inventory, Karnofsky Performance Status, Charlson 
Comorbidity Index and a demographic/health history form to assess study 
variables. 
Results 
Patients who were prescribed endocrine or hormonal therapy had higher 
symptom severity scores than did women who did not receive these therapies. 
26 
No differences were noted in symptom burden and symptom interference 
between early- and long-term survivors or whether or not they had taken 
adjuvant therapy. As functional status increased, the patients' symptoms scores 
decreased. Comorbidities did not impact the symptom scores. 
Conclusions 
Breast cancer survivors continue to experience symptoms, but symptoms are 
more severe among those taking hormonal or endocrine therapy. Understanding 
the relationship between symptoms, cancer therapy, comorbidities, and 
functional status in early versus late survivorship may improve symptom 
management and outcomes for breast cancer survivors. 
KeyWords 
Breast cancer, survivor, symptoms, symptom interference, M. D. Anderson 
Symptom Inventory (MDASI), Karnofsky Performance Status (KPS), Charlson 
Comorbidity Index (CCI) 
Breast cancer is the most common cancer (excluding skin cancer) among 
women in the United States; one in eight women will develop the disease 
(American Cancer Society, 201 3). Overall , women treated for breast cancer have 
an 89% survival rate after 5 years and a 75% survival rate after 15 years 
(American Cancer Society, 2013). In 2006, the number of breast cancer 
survivors was estimated to be 2.6 million. By 2009 they numbered 2.7 million and 
as of 2012 there are over 2.9 million (American Cancer Society, 2013; National 
Cancer Institute, 2012). Earlier diagnosis and treatment and improvements in 
cancer care have enabled more women with breast cancer to live longer lives 
and, for many, cancer-free. 
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Many survivors who have completed their primary treatment (surgery, 
chemotherapy/biotherapy, and/or radiation therapy) may continue taking hormonal 
therapy. Once primary treatment is over, survivors expect their symptoms to 
subside. Unfortunately many breast cancer survivors continue to have long-lasting 
symptoms related to their cancer and/or its treatment (Barsevick, 2007; Cleeland, 
2007; Janz et al., 2007; Rosedale and Fu, 2010). 
Multiple symptoms that persist are known as symptom burden (Burkett and 
Cleeland, 2007; Gapstur, 2007; Gill, Chakraborty, and Selby, 2012). Symptom 
burden is the subjective, quantifiable prevalence, frequency, and severity of 
symptoms and encompasses the patient's perception of the symptoms' impact 
(Cieeland, 2007; Gapstur, 2007). 
Symptom burden has been evaluated, but much of the research has 
focused on symptoms and supportive care during primary therapy (Chung, 
Cimprich, Janz, and Mills-Wisnesky, 2009). However, several studies have 
concentrated on the early survivorship periods--beginning and continuing 
through the first 27 months following completion of primary therapy (Brant et al. , 
2011; Ganz, Kwan, Stanton, Bower, and Belin , 2011 ; Janz et al. , 2007; Park, 
Bae, Jung, and Kim, 2011 ; Penttinen et al. , 201 0; Thompson, 2007; Yi , Swartz 
and Reyes-Gibby, 2011 ). Findings suggest that symptoms related to primary 
therapy contribute to impaired quality of life (Bower, 2009; Dahl, Nesvold , 
28 
Reinertsen , and Fossa, 2011; Janz et al., 2007; Park et al., 2011 ). The 
symptoms most frequently cited in the aforementioned studies include pain, 
fatigue or lack of energy, difficulty sleeping , arm pain and lymphedema, breast 
symptoms, feeling irritable or nervous, menopausal symptoms, weight changes, 
nausea, depression, and cognitive dysfunction. 
A number of studies have focused on a specific symptom, such as pain 
(Lundstedt et al. , 2012; Mao et al. , 2009; Rief, Bardwell, and Dimsdaile, 2011), 
lymphedema (Armer and Stewart, 2010; Meeske et al. , 2009; Smoot et al. , 
2010), fatigue (Bower et al. , 2008; Bower, Ganz, Irwin, Arevalo, and Cole, 2011 ; 
Thompson, 2007) or menopausal symptoms (Leining et al. , 2006; Loibl, 
Lintermans, Dieudonne, and Neven, 2011 ; Ruddy et al. , 2011 ). Other studies 
have explored longer-term issues. For example, the incidence of lymphedema 
was found to persist and/or increase over five years (Armer and Stewart, 201 0; 
Norman et al., 2009). Cancer-related fatigue was cited by 21 % of both the 1- to 
5-year survivors and the 5- to 1 0-year survivors (Bower et al. , 2008). Sleep 
disturbances, fatigue, and pain had persisted in survivors evaluated at an 
average of 4.2 years (Hartl et al. , 2003). 
Several studies have yielded contradictory findings. For example, the 
results of one study suggested that cognitive dysfunction abated in the 12 to 24 
months after adjuvant chemotherapy (Castellon et al. , 2004). Jim et al. (2009), 
however, found significant differences in cognitive functioning and cognitive 
impairment after six months among women who had received chemotherapy or 
radiation therapy compared to healthy matched controls. Tannock et al. 's 2004 
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review found durable cognitive effects in 9 to 75% of patients, although the 
higher percentages were observed among those evaluated closer to completion 
of chemotherapy. However, in a study of longer-term survivors (5 to 15 years), 
Klein et al. (2011) found an improvement in all symptoms except cognitive 
functioning and insomnia. The discrepancies among these findings may be 
attributable to variability in primary therapy over time, pre-existing comorbidities, 
or use of adjuvant endocrine or hormonal therapy. 
The likelihood of poor health was much higher among those who had 
another comorbid condition (Elliott et al. , 2011). Other studies have excluded 
participants who had an additional significant chronic illness (Thompson, 2007). 
Functional status has been addressed in previous studies and low functional 
status is associated with poorer quality of life (Penttinen et al. , 201 0). 
Symptoms may arise from comorbid illnesses or acute injuries related to 
the disease itself, or they may be attributable to cancer treatment and manifested 
in the form of side effects or toxicities (Cieeland, 2007). Symptom burden 
(Cieeland, 2007; Gapstur, 2007) is the conceptual framework chosen for this 
study. Symptom burden has been described as the subjective counterpart to 
tumor burden (Cieeland and Reyes-Gibby, 2002) and as the sum of the severity 
and impact of symptoms (Cieeland, 2007). Symptom burden affects multiple 
patient outcomes, including survival, functional status, and quality of life 
(Gapstur, 2007). Symptom burden is active and changes over time as patients 
undergo treatment or experience exacerbations or remissions of their disease 
(Vig and Pearlman, 2003). In this framework, symptoms related to treatment 
often are viewed as complicating post-treatment recovery (Cieeland, 2007; 
Cleeland and Reyes-Gibby, 2002). 
Historically, the symptoms of survivors during primary therapy or shortly 
thereafter have been addressed in the literature. But no studies have identified 
and compared the symptoms related to the use of adjuvant endocrine or 
hormonal therapy that are experienced by early- and long-term breast cancer 
survivors. 
The primary objective of this study was to determine whether symptom 
burden differed by survivor status (early versus long-term) and/or the use of 
endocrine or hormonal therapy. We hypothesized that no difference would be 
seen in the symptoms expressed among early- and long-term survivors. 
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This study also explored the association of comorbidities and symptoms 
expressed by early- and long-term survivors. Evaluation of concurrent 
comorbidities was warranted because comorbidities have been associated with 
symptom severity (Kurtz, Kurtz, Stommel et al.1999). This study also addressed 
the associations between functional status and symptoms related to adjuvant 
endocrine or hormonal therapy. 
Materials and Methods 
Study design 
The study design was exploratory and cross-sectional. Institutional Review 
Board approval was obtained, and all subjects provided informed consent. 
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Setting 
The study was conducted at the Nellie B. Connally Breast Center at The 
University of Texas MD Anderson Cancer Center, an academic, comprehensive 
cancer center. MD Anderson is the largest institution in The University of Texas 
system, with 631 inpatient beds and 1 ,281 ,489 outpatient visits in 2012. The 
Nellie B. Connally Breast Center served more than 4, 720 new patients and 
consultation visits, and conducted more than 33,000 follow-up visits in 2012. 
Study Participants 
The participants were adult women who had completed primary treatment 
for breast cancer (surgery, chemotherapy/biotherapy, and/or radiation) as many 
as six years earlier and were receiving follow-up care at the Breast Center. Non-
English speaking women were recruited with the assistance of the MD 
Anderson's Language Assistance office. Exclusion criteria included diagnosis of 
non-invasive, metastatic, inflammatory, or recurrent breast cancer or current 
active treatment with chemotherapy or biotherapy. Participants could be taking 
adjuvant hormonal or endocrine therapy. The patients were consecutively 
recruited as they presented to the Breast Center for a routine follow-up visit and 
were stratified by time (early: 0 to 36 months after primary treatment versus long-
term: 37 to 60 months after primary treatment), disease stage (1, II, or Ill), and 
whether or not they were taking adjuvant hormonal or endocrine therapy. 
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Sample Size 
Using a 2 x 2 factor analysis model, with 33 survivors per cell (long/short-
term survival by adjuvant endocrine therapy) , we had 80% power to detect a one-
unit difference in mean symptom burden scores through the use of adjuvant 
endocrine therapy. This translates into a standard deviation among means of 
0.5. We also had more than 95% power to detect a two-unit difference between 
early- and long-term survivors-the same as a 1.0 standard deviation among 
means-and to detect a 1.12 standard deviation among means for the interaction 
effect. All testing was 2-sided, using a 5% level of statistical significance. A 
subject standard deviation of 2.0 was used to calculate power, based upon 
findings by Cleeland (2007). Because we had two primary objectives (the main 
effect of short/long-term survival and the effect of adjuvant endocrine/hormonal 
therapy), we had a 10% chance of falsely rejecting at least one of our primary 
hypotheses. 
Data Collection Procedures 
Study participants were identified , gave their informed consent, and were 
enrolled during their routine follow-up outpatient clinic visit to the Breast Center. 
Once enrolled, each participant completed the MD Anderson Symptom Inventory 
(MDASI). The principal investigator determined each patient's Karnofsky score, 
completed the demographic and health history questionnaire with the participant, 
and extracted the treatment history from the electronic medical record. 
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Instruments 
Demographic/health history questionnaire. The demographic/health 
history questionnaire includes age, educational status, race/ethnicity, primary 
language spoken, menstrual status, work status, comorbidities, treatment history, 
and use of any adjuvant hormonal therapy. 
MD Anderson Symptom Inventory (MDASI). The MDASI was used to 
measure symptom severity, interference, and burden. The MDASI is a 19-item 
self-report measure of the severity and impact of cancer-related symptoms 
(Cieeland et al, 2000). It addresses 13 core symptoms: fatigue, sleep 
disturbance, pain, drowsiness, poor appetite, nausea, vomiting , shortness of 
breath, numbness, difficulty remembering, dry mouth, distress, and sadness 
using a numerical rating scale of 0 (not present) to 10 (as bad as you can 
imagine). Six additional items address how much the symptoms have interfered 
with the patient's life during the past 24 hours, using a numerical scale of 0 (did 
not interfere) to 10 (interfered completely) regarding general activity, mood, work 
(including work around the house), relations with other people, walking, and 
enjoyment of life. Symptoms may be categorized as 0-4 mild, 5-6 moderate, and 
7 or above severe; ratings of 5 or higher indicate a moderate-to-severe symptom 
that significantly impairs daily function ing (Mendoza et al. , 2013). The MDASI 
takes approximately 5 to 7 minutes to complete. The inventory has demonstrated 
internal consistency (reliability) with a coefficient alpha of 0.82, and its validity 
has been establ ished with factor analysis (Paice, 2004) in many different studies. 
The MDASI has been psychometrically and linguistically val idated in nine 
languages and linguistically validated in another 14 languages in addition to 
English. The MDASI was used to evaluate symptoms over the previous week, 
rather than 24 hours. Internal consistency of the MDASI for this study was 
measured by Cronbach's alpha= 0.91. 
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Charlson Comorbidity Index (CCI). The CCI was used to measure 
comorbidities. The CCI is an investigator-completed index that measures 17 
clinical conditions that are weighted to assess the effect of the conditions on the 
patient's prognosis (Charlson, Pompei, Ales, and MacKenzie, 1987). Item scores 
range from 1 to 6 for each item and are based on the relative risk for each. 
Scores range from 0 to 34, with higher scores signifying greater comorbidity. One 
of the ten comorbidity items on the CCI is cancer, thus each subject began with a 
score of two. The CCI has an established reliability with clinical conditions, 
including cancer (Hall, Ramachandran, Narayan, Jani, and Vijayakumar, 2004). 
Karnofsky Performance Status (KPS). Patients' functional status was 
measured with the Karnofsky Performance Status. The KPS is a clinician- or 
investigator-completed scale that classifies patients according to their degree of 
functional impairment on a scale from 0 (deceased) to 100 (normal, no 
complaints, no evidence of disease) (Schag, Heinrich, and Ganz, 1984). The 
KPS is further divided into three subgroups: A) Able to carry on normal activity 
and to work, with no special care needed (80-1 00), B) unable to work, able to live 
at home and care for most personal needs, varying amounts of assistance 
needed (50-70), and C) Unable to care for self, requires equivalent of institutional 
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or hospital care; disease may be progressing rapidly (0-40). The KPS has shown 
reliability and validity previously with a Cronbach's alpha of 0.97 and construct 
validity demonstrated with a p<0.001 (Mor, Laliberte, Morris, and Wiemann, 
1984; Schag et al., 1984). 
Statistical Analysis 
The objectives of this study were to determine whether symptom burden 
differed between survivor status (early/long-term) and/or endocrine or hormonal 
adjuvant therapy use. Early survivors were defined as those who had finished 
primary treatment fewer than three years or 36 months prior to the date of the 
survey. Long-term survivors were defined as those who had finished their 
primary treatment at least three years, but less than six years (37 to 60 months), 
before the date of the survey. 
Descriptive statistics were used to assess the distributional characteristics 
and demographics of the study population across survivor status and use of 
hormonal therapy. Chi-squared, Fisher's exact test, and t-test were conducted to 
determine whether these characteristics differed by survivor status as well as by 
the presence or absence of current adjuvant endocrine or hormonal therapy. 
Symptom burden and interference were calculated separately according to the 
prorated score recommended by theM. D. Anderson Symptom Inventory User 
Guide. 
A two-way ANOVA model was conducted to evaluate differences in 
symptom burden, symptom interference, and burden/interference of individual 
symptoms. We conducted another set of ANOVA models with the KPS and the 
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Charlson Comorbidity Index (CCI) to evaluate the impact of functional status and 
comorbidities on symptoms. A third two-way ANOVA model was used to 
evaluate differences in the individual MDASI items by survivor status and 
hormone therapy treatment. All models contain terms for stage to account for 
stratification on that factor, as well as age for the effects of age upon symptom 
severity and interference. The interaction between the two factors was tested in 
all models but was dropped if the term was non-significant. Cronbach's alpha 
was used to measure the internal consistency of MDASI with severity (a= 0.84), 
interference (a= 0.88), and overall MDASI (a= 0.91). 
Results 
A total of 141 patients were sequentially approached to participate in the 
study over a period of four months; 134 agreed to participate. Individuals who 
chose not to participate did so primarily because of time constraints. One 
individual withdrew her consent, leaving 133 study participants. 
Patients and Disease Demographics 
Patient characteristics, both demographic and disease-related, were well 
balanced between survival status and use of adjuvant therapy (Table 1). 
Subjects were predominantly white, non-Hispanic (65.4%), English-speaking 
(89.5%), married (72.7%), had a high school education (30.8%), and were a 
mean age of 56 (range, 30.5-83.0) The majority had estrogen receptor- positive 
(58.6%), Her2/neu-negative (80.5%) disease. Disease stage was stratified by 
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design, with equal numbers of stage I, II, and Ill in both arms (early and long-
term). The majority had received chemotherapy (74.2% taxane, 68.3% 
anthracycline, and 9.8% other), but only 19.5% received trastuzumab. More 
women had undergone modified radical or total mastectomy (56.4%) than 
segmental mastectomy (45.9%). About half had undergone sentinel lymph node 
biopsy only (48.9%), half (51 .1 %) had axillary node dissection, and 78.2% of 
participants received adjuvant radiation therapy. 
Primary Treatment History 
In general, treatment history among early- and long-term survivors was 
not statistically significant, except for taxane chemotherapy and adjuvant therapy. 
Early survivors were more likely to have been treated with taxanes than were 
long-term survivors (82.8% vs. 66.2%; p=0.0289). In addition, women who were 
not on adjuvant therapy were more likely to have received primary treatment with 
taxanes (87.7% vs. 61.2%; p=0.0005) . Receipt of anthracycline chemotherapy 
did not differ among early- vs. long-term survivors. The type of breast and axillary 
surgery was not statistically significant for these groups. Women who received 
adjuvant therapy were more likely to have received radiation therapy (p=0.0426). 
MDASI Results 
Summary statistics for all the MDASI items are shown in Table 2. The 
frequency of reported symptoms and their severity/interference are shown in 
Table 3. No statistical evidence for a relationship between comorbidities and 
MDASI scores was observed; however, this patient population had few 
comorbidities as indicated by the low CCI scores in general. As the Karnofsky 
Performance scores increased, MDASI scores decreased but not significantly, 
indicating that individuals with greater performance status had lower symptom 
severity. 
Symptom frequency and severity 
All but five of the women reported experiencing at least one symptom. 
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Most women (81 .2%) endorsed five or more symptoms. The majority of 
symptoms were in the mild to moderate categories, although 44% of women 
scored at least one symptom in the severe range (7 or higher). Fatigue was the 
most commonly reported symptom, whereas sleep disturbance was rated highest 
in severity. 
Symptom severity and survivor status 
Survivor status did not significantly impact the MDASI scores, and no 
significant difference was noted· between early or long-term survivors in relation 
to reports of symptom severity. The interaction term between survivor status and 
adjuvant endocrine or hormonal therapy use was non-significant in all models, 
indicating no differences in symptom burden and interference between early and 
long-term survivors, regardless of adjuvant therapy use. 
Symptom severity and adjuvant therapy use 
Patients who had endocrine or hormonal therapy had higher symptom 
severity scores than did the women who did not, as reflected in the MDASI 
scores (1-1 = 29.1 vs. 1-1 = 22.0; p = 0.0250) 
Symptom severity and Karnofsky Performance Status 
Karnofsky Performance Status was significantly related to pain (p = 
0.0004), fatigue (p = 0.0217), sleep (p = 0.0249), distress (p = 0.0040), 
remembering things (p = 0.0292) ,and numbness (p = 0.0195), with lower KPS 
scores being related to higher symptom severity. 
Symptom Severity and Charlson Comorbidity Index 
The Charlson Comorbidity Index was significantly related only to symptoms of 
nausea (p = 0.0000) and vomiting (p = 0.0050). 
Discussion 
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This study sought to examine the occurrence of symptom burden in early 
and long-term survivors with or without endocrine or hormonal adjuvant therapy 
use. Data suggested few statistically significant relationships between and 
among study variables. However, as would be expected for women taking 
adjuvant endocrine or hormonal therapy, these survivors had significantly higher 
symptom severity scores than did the women who did not receive these 
therapies. This finding may be attributable to the side effects of the hormonal or 
endocrine adjuvant therapies, including hot flashes, fatigue, insomnia, or 
headaches (Bowles, et al., 2012). Pain is another commonly reported symptom 
(Dunn & Gotay, 2013). Although clinicians discuss with their patients that the 
symptoms related to hormonal or endocrine therapy may improve over time, no 
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significant differences are seen in the scores of early versus long-term survivors 
who receive these therapies. The assumption was that closer to primary 
treatment, the survivor would experience certain symptoms that would resolve 
over time, although other symptoms might persist. Therefore, from clinical 
experience, we expected that long-term survivors would have fewer symptoms 
overall. However, our results suggest that women continue to experience multiple 
symptoms after treatment completion. Few studies have evaluated symptoms 
five years after diagnosis (Koch et al. , 2013), when routine follow-up care has 
ended. This emphasizes the need to continue to assess symptom burden 
throughout the cancer treatment trajectory. 
The median age of the participants was 56, which is lower than the 
median age of 61 for breast cancer diagnosis in the United States (American 
Cancer Society, 2013). It is unclear why our participants were younger. It may be 
that younger women are referred to our institution more often or that younger 
women tend to participate in research studies, but this finding reflects the 
literature, which often reveals a younger median age (Bower et al., 2006; 
Broeckel, Thors, Jacobsen, Small, and Cox, 2002; Carlson, Campbell, Garland 
and Grossman, 2007; Eversley et al., 2005; Otte, Carpenter, Russell , Bigatti, 
andChampion, 201 0). The younger age of our patients may affect the symptoms 
expressed; as in previous studies, older women tended to minimize and attribute 
any symptoms they had to aging (Heidrich, Egan, Hengudomsub, and Randolph, 
2006; Reiland and Heidrich, 2011; Royer, Phelan, and Heidrich, 2009) 
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Women with more symptoms have poorer functional status, whereas 
women with fewer symptoms have higher functional status scores. Our study 
bolstered these findings; as the Karnofsky Performance scale increased (nearer 
to 100 or normal function) , the MDASI scores decreased (i.e. , fewer symptoms or 
lower symptom burden). All study participants had completed primary therapy 
and were without evidence of disease, and they all scored at least an 80 on the 
KPS scale, which indicates the ability to carry on normal activity and to work. 
Multiple studies have noted the most prevalent symptoms in breast cancer 
survivors to be pain, fatigue, disturbed sleep, cognitive problems, and mood 
(Dodd, Cho, Cooper, and Miaskowski, 201 0). Our study had similar findings 
(Table 3), with the top five symptoms reported as fatigue, remembering things, 
disturbed sleep, pain, and feeling drowsy, although our study participants 
reported mood complaints less often. Vomiting was the least frequently reported 
symptom, as would be expected of women who had completed primary therapy. 
One unexpected finding was how often these survivors reported dry mouth. Dry 
mouth is not a symptom that is often reported as a concern in the clinical setting. 
In general, most survivors reported mild to moderate symptoms. 
These data suggest persistence of mild to moderate symptom burden 
following breast cancer treatment regardless of survivor status. Statistically 
significant findings suggesting increased symptom severity for women receiving 
adjuvant endocrine or hormonal therapies identify a clinical opportunity to assess 
which symptoms develop at what point in time as a means of further addressing 
those symptoms and developing interventions. Moreover, for patients who 
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require more than the current five years of adjuvant therapy with hormonal or 
endocrine agents, this study identifies the need for attentive assessment of 
continued symptoms longer into survivorship for this population. Although few 
statistically significant relationships were found between and among other study 
variables, the impact of adjuvant therapy on female breast cancer patients' post-
treatment symptom severity offers valuable insight for clinical practice. 
Strengths and Limitations 
One of the strengths of this study was the emergence of evidence 
indicating that symptom burden persists for women treated for breast cancer in 
both an early and long-term survivorship time frame. This finding adds to the 
existing literature related to symptom burden during and immediately following 
treatment. Moreover, symptom burden may be exacerbated by prolonged 
endocrine or hormonal adjuvant therapy. These findings inform clinical practice, 
which focuses on evaluating and managing symptom burden throughout 
survivorship, even after the completion of primary therapy. 
This study had several limitations. Because this was a cross-sectional 
study, the duration of the symptoms could not be evaluated. Sampling bias may 
have occurred as participants were recruited from the Breast Center while they 
were there for a routine visit and therefore were not randomly selected. In 
addition, because this study was performed at only one cancer center, the results 
may not be generalizable to patients in other centers. Moreover, the majority of 
women in this study were married, white, non-Hispanic, employed full-time, high 
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school graduates-demographics that are not reflective of national data and may 
not be generalizable to minorities or other groups. Women of other races or 
ethnic groups may experience different symptoms. In addition, male breast 
cancer survivors were excluded from this study, are underrepresented in the 
literature, and may also experience different symptoms. 
Research Implications 
Although the number of participants who reported severe symptoms was 
low, most survivors reported at least one symptom (96%) , and the majority of 
survivors in this study reported five or more. The most common, severe, and 
distressing symptoms need further evaluation. Longitudinal studies that compare 
survivors to healthy women are needed in order to characterize symptom 
incidence and persistence over time. Further research should be directed toward 
assessing the long-term impact of symptoms and evaluation of symptom 
distress. In addition, studies that comprise participants who reflect the age of the 
U. S. breast cancer population are needed, as are studies with minority 
populations that can provide insight into the symptom experiences of breast 
cancer survivors who are minorities. 
Clinical Implications 
Clinicians who care for breast cancer survivors need to be aware that the 
majority of these survivors, whether early or long-term, have symptoms, and that 
those who are on adjuvant hormonal or endocrine therapy experience greater 
symptom severity. Although most women in this study did not have significant 
44 
distress, assessment of the presence and severity of symptoms should be a 
routine part of oncology care. Clinicians can then provide anticipatory guidance 
and inform survivors about the persistence of symptoms. This will enable 
survivors to anticipate symptoms and will encourage development of programs to 
assist survivors in dealing with symptoms more effectively. 
Conclusions 
We conducted this study to evaluate symptoms experienced by breast 
cancer survivors who completed primary therapy. From clinical experience, we 
expected symptoms to lessen over time, and surmised that long-term survivors 
would have fewer symptoms. Our analysis revealed that both early and long-term 
survivors had symptoms, but those taking adjuvant endocrine or hormonal 
therapy experienced greater symptom severity, whether early- or long-term. 
Establishing this baseline will help to develop pilot interventions that can be 
tested and used effectively in this population. Understanding the connections 
among symptoms, cancer therapy, comorbidities, and functional status may 
result in improved symptom management and outcomes for breast cancer 
survivors. 
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Table 1 
D h . b t t emograpi 1cs >y SUfVIVOr S a US an d d . /h en ocnne armona lth erapy 
Survivor Status Adjuvant endocrine or hormonal therapy 
Early n = 65) Long n = 68) No (n = 65) Yes (n = 68) Total (n = 133) 
Characteristic N % N % N % N % N % 
Age(Mean) 54.7 10.9 57.3 11.4 54.6 10.7 57.5 11.5 56.0 11.2 
Medication 
None 32 49.2 33 48.5 65 100 0 0.0 65 48.9 
Anastrazole 13 20.0 18 26.5 0 0.0 31 45.6 31 23.3 
Exemestane 0 0.0 1 1.5 0 0.0 1 1.5 1 0.8 
Letrozole 8 12.3 4 5.9 0 0.0 12 17.6 12 9.0 
Tamoxifen 12 18.5 12 17.6 0 0.0 24 35.3 24 18.0 
ER 
Negative 26 40.0 29 42.6 54 83.1 1 1.5 55 41.4 
Positive 39 60.0 39 57.4 11 16.9 67 98.5 78 58.6 
PR 
Neqative 32 49.2 31 45.6 56 86.2 7 10.3 63 47.4 
Positive 33 50.8 37 54.4 9 13.8 61 89.7 70 52.6 
Her2 
Negative 53 81 .5 54 79.4 47 72.3 60 88.2 107 80.5 
Positive 12 18.5 14 20.6 18 27.7 8 11 .8 26 19.5 
Marital Status 
Divorced 7 10.9 12 17.6 13 20.3 6 8.8 19 14.4 
Married/Partnered 47 73.4 49 72.1 41 64.1 55 80.9 96 72.7 
SEJparated 3 4.7 0 0.0 1 1.6 2 2.9 3 2.3 
Single, living alone 4 6.3 2 2.9 4 6.3 2 2.9 6 4.5 
Sinqle, livinq w/adult 1 1.6 1 1.5 2 3.1 0 0.0 2 1.5 
Widowed 2 3.1 4 5.9 3 4.7 3 4.4 6 4.5 
Race 
Asian/Pacific Islander 2 3.1 0 0.0 0 0.0 2 2.9 2 1.5 
Black Non-Hispanic 14 21 .5 10 14.7 12 18.5 12 17.6 24 18.0 
Hispanic 8 12.3 11 16.2 8 12.3 11 16.2 19 14.3 
Other 1 1.5 0 0.0 1 1.5 0 0.0 1 0.8 
White Non-Hispanic 40 61.5 47 69.1 44 67.7 43 63.2 87 65.4 
Staqe 
I 19 29.2 24 35.3 20 30.8 23 33.8 43 32.3 
II 22 33.8 23 33.8 22 33.8 23 33.8 45 33.8 
Ill 24 36.9 21 30.9 23 35.4 22 32.4 45 33.8 
Karnofsky Performance Status 
80 16 24.6 8 11.8 7 10.8 17 25.0 24 18.0 
90 23 35.4 34 50.0 27 41.5 30 44.1 57 42.9 
100 26 40.0 26 38.2 31 47.7 21 30.9 52 39.1 
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Table 1 cont'd: 
D h" b t t emograp, tcs 'Y survtvor s a us an d d . (h en ocnne armona I th erapy 
Survivor Status Adjuvant endocrine or hormonal therapy 
Early (n = 65) Long (n = 68) No (n = 65) Yes (n = 68) Total (n = 133) 
Characteristic N % N % N % N % N % 
Charlson Comorbidit" Index 
2 51 78.5 48 70.6 51 78.5 48 70.6 99 74.4 
3 12 18.5 13 19.1 12 18.5 13 19.1 25 18.8 
4 1 1.5 7 10.3 1 1.5 7 10.3 8 6.0 
5 0 0.0 0 0.0 1 1.5 0 0.0 1 0.8 
Chemotaxane 
No 11 17.2 23 33.8 8 12.3 26 38.8 34 25.8 
Yes 53 82.8 45 66.2 57 87.7 41 61 .2 98 74.2 
Chemoanthracycline 
No 16 24.6 26 38.2 13 20.0 29 42.6 42 31 .6 
Yes 49 75.4 42 61.8 52 80.0 39 57.4 91 68.4 
Chemo-other 
No 58 89.2 62 91.2 58 89.2 62 91.2 120 90.2 
Yes 7 10.8 6 8.8 7 10.8 6 8.8 13 9.8 
Trastuzumab 
No 53 81 .5 54 79.4 47 72.3 60 88.2 107 80.5 
Yes 12 18.5 14 20.6 18 27.7 8 11 .8 26 19.5 
XRT 
No 15 23.1 14 20.6 19 29.2 10 14.7 29 21.8 
Yes 50 76.9 54 79.4 46 70.8 58 85.3 104 78.2 
Segmental mastectomy 
No 35 53.8 37 54.4 36 55.4 36 52.9 72 54.1 
Yes 30 46.2 31 45.6 29 44.6 32 47.1 61 45.9 
MRM or total mastectomy 
No 27 41 .5 31 45.6 28 43.1 30 44.1 58 43.6 
Yes 38 58.5 37 54.4 37 56.9 38 55.9 75 56.4 
SLN only 
No 34 52.3 34 50.0 31 47.7 37 54.4 68 51.1 
Yes 31 47.7 34 50.0 34 52.3 31 45.6 65 48.9 
AND 
No 31 47.7 34 50.0 34 52.3 31 45.6 65 48.9 
Yes 34 52.3 34 50.0 31 47.7 37 54.4 68 51.1 
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Table 2 
S t t" f n th MDASI ummary s a 1s 1cs or e 
Variable N Mean SD Min Max 
Core s~m12toms 
Pain 133 2.9 2.8 0 10 
Fatigue 132 3.4 2.5 0 10 
Nausea 132 0.5 1.7 0 10 
Sleep 131 3.3 3.0 0 10 
Distress 133 2.6 2.8 0 10 
Shortness of breath 133 1.0 1.9 0 9 
Remembering things 132 2.8 2.7 0 10 
Lack of appetite 133 0.8 1.7 0 9 
Drowsy 133 2.4 2.6 0 10 
Dry mouth 132 1.4 2.1 0 10 
Sad 133 2.2 2.7 0 10 
Vomit ing 133 0.1 0.6 0 6 
Numbness 133 2.4 2.8 0 10 
MDASI SEVERITY 133 25.7 18.2 0 92 
Interfer~nce items 
General activity 133 2.1 2.4 0 10 
Mood 133 2.0 2.4 0 10 
Work 133 2.3 2.7 0 9 
Relations 133 0.9 1.7 0 7 
Walking 133 1.9 2.6 0 9 
Enjoyment of life 133 1.4 2.1 0 9 
MDASI INTERFERENCE 133 10.6 11.1 0 42 
MD ASI 133 36.2 27.3 0 125 
Note. Cronbach's alpha's for Seventy (0.84), Interference (0.88), MDASI (0.91) 
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Table 3 
Symptom frequency, Percentage reported moderate/severe and the average symptom 
"t'iitm sevemy,m e erence score 
Variable N % Mean SD 
ModfSev 
Core S~mntoms 
Pain 92 42 4.2 2.4 
Fatigue 113 39 4.0 2.3 
Nausea 17 47 4.0 2.9 
Sleep 98 44 4.4 2.7 
Distress 90 33 3.8 2.6 
Shortness of breath 44 27 3.1 2.0 
Remembering things 104 34 3.6 2.5 
Lack of appetite 32 25 3.2 2.3 
Drowsy 92 34 3.5 2.5 
Dry mouth 59 22 3.2 2.0 
Sad 78 36 3.7 2.6 
Vomiting 4 25 3.0 2.2 
Numbness 84 29 3.7 2.6 
Interference Items 
General activity 78 32 3.5 2.2 
Mood 85 26 3.1 2.4 
Work 81 37 3.7 2.5 
Relations 49 20 2.6 2.0 
Walking 67 40 3.8 2.5 
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On 11 /14/2012 the Institutional Review Board 4 committee, chair, or designee granted approval 
to the above named and numbered protocol since the contingencies outlined by the IRB 4 on 
11/09/2012 have been met. 
It was noted that the protocol, informed consent documents (ICDs) and/or the Waivers of lCD and 
Authorization are satisfactory and in compliance with federal and institutional guidelines. No 
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If a Material Transfer Agreement (MT A) is required , it must be obtained prior to Activation. 
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Information for the Overall Principal Investigator- In addition to submitting an application to your organization's IRB (designated 
the "Reviewing IRB' ), an "Intent to Submit for Centralized Review" form must be submitted to the IRB office at each participating 
organization. 
Information for the Site Principal Investigator- The purpose of this form is to request centralized review at your organization 
(designated the "Relying Organization"). This request will be considered by your organization and a decision made on a case-by-case 
basis. The IRB office from your organization will forward the final decision to the Reviewing IRB. 
If your organization agrees to Centralized IRB Review, you will be required to submit additional materials in accordance with local 
policy. The review of local issues by your organization is a separate process from the IRB approval being sought by the Overall Pl. 
Reminder. you are not authorized to initiate research at your organization until both processes are completed: 1) the study is 
approved by the Reviewing IRB and an approval letter is issued, and 2) the local policy issues have been resolved and an activation 
letter has been issued by your Organization. 
Study Title: 
Department: 
PI 's Telephone#: 
PI's e-mail address: PI's FAX Number: 
flame of the Overall Principal Investigator (PI~ : 
Overall PI's Name (Last Name, First Name, Ml): 
Organization: I Af\ iJ Atyj<£ !iQo 
3. Which University of Texas Participating Organization will serve as the Reviewing IRB? 
Select only one 
UT at Arlington (UTA) UT Pan American UT Medical Branch (UTMB) 
-
UT Austin (UT Austin) UT Permian Basin UT HSC at Houston (UTHealth) 
-
UT Brownsville UT San Antonio (UTSA) UT HSC at San Antonio (UTHSCSA) 
UT at Dallas (UTD) UT Tyler UT Health Science Center Tyler 
- UT at El Paso (UTEP) UT Southwestern fX UT MD Anderson 
4. Which University of Texas Participating Organizations will be engaged in this research? 
Column A- Participating Organizations Column 8 -Institutions affiliated with the participating 
organization 
Select the Participating Organization(s) that will be engaged in Insert the institutions affiliated with the participating organization 
the research that will also be engaged in the research 
UT at Arlington (UTA) 
UT Austin (UT Austin) 
UT Brownsville 
UT at Dallas (UTD) 
UT at El Paso (UTEP) 
UT Pan American 
UT Permian Basin 




UT Medical Branch (UTMB) 
UT Centralized IRB Review 
Notification to Relying Organization 
Intent to Submit for Centralized Review 
UT Health Science Center at Houston (UTHealth) 
UT Health Science Center at San Antonio (UTHSCSA) 
UT Health Science Center Tyler 
UT MD Anderson 
FOR IRB OFFICE USE ONLy 
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HSC San Antonio 
HSC Tyler 
ll:::: MD Anderson 
3. Notifica tion Preference - the ReviewinCIIRB must notify this institution of approvals and study closure usinQ the followinQ method(s): 
D send a copy of the IRB letter D send a monthly statement of listing the protocols approved in the previous month 
D send a weekly statement of listing the w .-'Send an copy of the IRB letter to the Site PI at this protocols approved in the previous week organization who is then responsible to provide this infomnation to the Institution 
4. Federalwide Assurance lnfomnation- select the a licable statements 
The box that applies Subpart A to all research is checked 
The box that applies Subparts B. C. and D to all research Is checked 
5. Verifica lion th9! Reviewing IRB is listed on FWA 
g ...}Oe IRB designated in Item 3 above is listed on this institution's Federalwide Assurance 
i[B" The IRB designated in Item 3 above is also l isted on the Federalwide Assurance for each 
affiliated institution listed in Item 4, Column B 
6. Signature of the Official Authorized by Organization: 
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UT-H- SN - Nursing 
FROM: Cynthia Edmonds, MLA 
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Office of Research Support Committees 
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RE: HSC-SN-12-0880 
Symptoms in Early and Long-term Breast Cancer SuNivors 
Reference Number: 091363 
Dear Ms. Strunk, 
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This is a confirmation letter that the Committee for the Protection of Human Subjects 
(CPHS), the Institutional Review Board at the University of Texas Health Science Center 
at Houston, has received all the applicable documents for the above referenced protocol. 
The CPHS agrees to rely on the reviewing IRB, MD Anderson Cancer Center, which 
granted approval on November 9, 2012. It is your responsibility to maintain approval 
with the MDACC lRB and renew your protocol per their schedule. 
Please feel free to contact the Committee for the Protection of Human Subjects (CPHS) 
at 713-500-7943 if you have any additional questions or concerns. 
Appendix D 
Letter of Support 
64 
- HE UNIVERSITY OF TEXAS 
.MD Anderson 
Gancei-Center 
Making Cancer History' 
December 12, 2012 
Faith A. Strunk, MSN, RN, FNP 
65 
VICente Valero. MO, FACP 
Professor of Medicine. Nellie S. Connally !lre~st Center 
Chairman ,\d·lnterlm. Deparunentof Breast Medical Oncology 
Clinical Director. Morgan Welch Innammatory Breast Cancer 





Breast Medical Oncology -Unit 1354 
1515 Holcombe Blvd , Houston, TX 77030 
The University of Texas Health Science Center School of Nursing 
6901 Bertner Avenue 
Houston, TX 77030 
RE: Letter of Support- Symptoms in Early and Long-term Breast Cancer Survivors Who 
Have Completed Primary Therapy 2012-0909 
Ms. Strunk: 
This letter acknowledges your interest in conducting the above study in the Nellie B. Connelly 
Breast Center at the University of Texas MD Anderson Cancer Center. I believe your study 
will make valuable and important contributions, and we look forward to supporting you and 
your research, which involves 132 participants from the Breast Center. 
I thank you for the opportunity to work with you on this study. Our patients depend upon 
exciting and quality research like this to give them hope. 
Vicen e Valero, M.D., F.A.C.P. 
Chairman Ad-Interim 
Professor of Medicine 
VV /bmc 
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1. Birth date: Month_Day ___ Year __ 
2. Participant's marital status (at present): 
Married/Partnered D Separated D 
Divorced D Single, living with another adult 0 
Widowed , D Single, living alone D 
3. Race: 
Asian or Pacific Islander 
Black Non-Hispanic 






White Non-Hispanic D 
Other (Specify) D 
4. Primary language spoken:_ 
5. Education (Mark only the highest completed): 
High School D Associate D 
Bachelors 0 Masters D 
PhD 0 Technical School 0 
Other_ 
6. Job status (check the one that best describes your status): 
Employed outside the home, fulltime D Unemployed D 
Employed outside the home, part time D Retired 0 
Disabled due to illness D Work at home D 
7. Menstrual status (check the one that best describes your status): 
Premenstrual (still having periods) 0 
Perimenopausal (usual pattern of periods is altered) 0 
Postmenopausal (no periods for one year or more) D 
8. Other health problems: Have you been diagnosed by a health care 
provider with any chronic medical conditions? Please list them 
below. If yes, has this condition limited your current daily activities? 
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Appendix F 
M.D. Anderson Symptom Inventory 
Copyright 2000 The University of Texas M. D. Anderson Cancer Center 
All rights reserved 
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Date:-------- Institution:. _______ _ 
Participant Initials:----- Hospital Chart#:. _____ _ 
Participant Number:-----
~Ol As Bad Aa You 
,resent Can Imagine 
0 1 2 3 4 5 6 7 8 9 10 
·1. Your feeling sad at ~s WORST? o : 0 0 : o . 0 0 0 o : 0 : o : 0 
12. Your vomiting at its WORST? o : o : o o : o : o:o 0 : 0 : 0 : 0 : 
13. Your numbness or tingling at 
its WORST? 
. ' ' ' 
0 : 0 : 0 : 0 : 0 : 0 : o: o: o: 0 : 0 
_. _ _ , _ 
Part II. How have your symptoms Interfered with your life? 
Symptoms frequently interfere with how we feel and function. How much have your symptoms interfered with 
the following items In the last 24 hours: 
Old Not lntelfenad 
Interfere Complete~ 
0 1 2 3 4 5 6 7 8 9 10 
14. General activity? 0 : 0 : 0 o: 0 0 0 0 0 0 0 
' 
15. Mood? 0 : 0 : 0 : 0 : o : o: 0 0 0 0 0 
16. Work (including work around 0 : o: o: o: o: o : 0 0 0 0 0 the house)? 
; 
17. Relations with other people? o : o : 0 o: o : 0 0 0 0 0 0 
18. Walking? o : o: o: o: o : o: 0 0 0 0 0 
....- - -. ---
19. Enjoyment of life? o : 0 o : 0 o · o : c 0 
Copyright 2000 The University of Texas M. D. Anderson Cancer Center 
All rights reserved 
0 c 0 
-· 
Appendix G 
Karnofsky Performance Scale 
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KARNOFSKY PERFORMANCE SCALE 
Description 
100 Normal, no complaints, no evidence of disease 
90 Able to carry on normal activity; minor signs or symptoms of disease 
80 Normal activity with effort; some signs or symptoms of disease 
70 Cares for self, unable to carry on normal activity or to do active work 
60 Requires occasional assistance, but is able to care for most of 
his/her needs 
50 Requires considerable assistance and frequent medical care 
40 Disabled, requires special care and assistance 
30 Severely disabled, hospitalization indicated. Death not imminent 
20 Very sick , hospitalization indicated. Death not imminent 




Charlson Comorbidity Index 
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Charlson Comorbidity Index 
Weight Condition 
1 D Myocardial infarct 
D Congestive heart failure 
D Peripheral vascular disease 
D Cerebrovascular disease 
D Dementia 
D Chronic pulmonary disease 
D Ulcer disease 
D Mid liver disease 
D Diabetes 
2 D Hemiplegia 
D Moderate or severe renal disease 
D Diabetes with end-organ damage 
D Any tumor 
D Leukemia 
D Lymphoma 
3 D Moderate or severe liver disease 





SUBJECT LOG PROTOCOL 2012-0909 
ACCESSION# DATE STAGE & RECEPTOR STATUS TIME TIME 
ENROLLED TNM IN OUT 
Appendix J 
Subject Log by Stage 
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SUBJECT LOG BY STAGE PROTOCOL 2012-0909 
YES Adjuvant Early {1-3 YRS) NO Adjuvant EARLY (1-3 YRS) 
Hormonal/Endocrine Tx 0-36 mos Hormonal/Endocrine Tx 0-36 mos 
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Permission to use the Charlson Comorbidity Index 
-----Original Message-----
From: Mary E. Charlson, MD [mailto:mecharl@med.cornell.edu] 
Sent: Friday, September 21, 2012 2:29 PM 
To: Strunk, Faith A 
Subject: RE: permission for use of Charlson Comorbidity Index 
Good Afternoon, 
You may use the index for your study. 
Best, 
Mru.:y Charlson 
From: Strunk, Faith A [Faith.A.Suunk@uth.tmc.edu] 
Sent: Thursday, September 20, 2012 3:23 PM 
To: Mary E. Charlson, MD 
Subject: permission for use of Charlson Comorbidity Index 
Dear Dr. Charlson, 
85 
I am Faith Strunk, a doctoral student at the University of Texas- Houston, Health Science 
Center School of Nursing. I am currendy planning a pilot study that is looking at symptoms 
in breast cancer patients who have completed primary therapy (surgery, 
chemotherapy / biotherapy and radiation) and the effects of time post-therapy and adjuvant 
endocrine therapy. I am also exploring the effects of functional status and comorbidities on 
symptom severity and interference. Acknowledging the reliability, validity and applicability to 
my study population, I am writing to request your permission to use the Charlson 
Comorbidity Index in my study. 
I will cite your article: Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of 
classifying prognostic comorbidity in longitudinal studies: development and validation. J 
Chronic Dis. 1987;40(5):373-83 when we publish the results. 
Thank you for your time, 
Faith A. Strunk 
doctoral student 
University of Texas- Houston Health Science Center School of Nursing 
cell: 713-382-7204 
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Sent: Tuesday, October 16, 2012 4:49PM 
To: Strunk,Faith A 
Cc: synnptonnresearch 
Subject: RE: Order Fornn for Pain Research Group Assessnnent Tools 
I have attached the MDASI-core as you requested. Please let nne know if you have any 
questions. Thank you for your interest in the MDASI. 
The ennail that is sent with the tool is the authorization letter for all the non-funded 




Fronn: Faith Strunk [mailto: fastrunk@nndanderson.org] 
Sent: Friday, October 12, 2012 1:45PM 
To: synnptonnresearch 
Subject: Order Form for Pain Research Group Assessment Tools 
Order Fornn for Pain Research Group Synnptonn Assessnnent Tools 
Assessnnent Tool: M.D. Anderson Synnptonn Inventory (core MDASI) 
Psychonnetrically validated language(s): Chinese -
Simplified,English,Filipino,F rench, Greek,] apanese,Korean,Russian 
Linguistically validated language(s): 
Afrikaans,Arabic,Dutch, German,Hebrew ,Hindi,Italian,Portuguese - Brazil,Portuguese -
Portugal,Spanish,Swedish,Turkish,Vietnannese 
Purpose: Non-funded acadennic research 
Study Type: Descriptive study or survey 
Detailed description: 
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Much of the survivorship synnptonn literature has focused on synnptonns and supportive care 
during primary therapy, few studies have looked at breast cancer survivors much further 
than 2 years after connpleting primary therapy, and those that have, have contradictory 
results. Pain, fatigue, and sleep disturbances are nnost often found. This study will address 
88 
the symptoms experienced by early (less than 3 years after completion of primary therapy) 
and longer term survivors (years 3-5 after completion of primary therapy) . We will assess 
functional status, comorbidities and the experience of symptom burden expressed by the 
survivors. We will identify and compare the symptoms experienced by early and long-term 
breast cancer survivors related to the use of adjuvant endocrine therapy. 
Study ID: Symptoms in early and long-term survivors of breast cancer who have completed 
primary therapy 
Disease Type: Invasive breast cancer, stages I-III 
Mailing Address: 
First Name: Faith 
Last Name: Stmnk 
Title: 
Company: MDACC 
Department: Breast Medical Oncology 
Address: 1515 Holcombe Blvd Unit 1354 
City: Houston 
State: TX 
Country: United States 




Billing Address: Same as Mailing Address 
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Breast cancer is the most common cancer in women in the United States (excluding skin 
cancer); one in 8 women will develop it during her lifetime (American Cancer Society, 
2011). Overall women treated for breast cancer have an 89% survival rate after 5 years and 
75% after 15 years. The National Cancer Institute has estimated that there were 
approximately 2.7 million breast cancer survivors in the United States as of January 2009 
(2011). The number of all cancer survivors is projected to grow by 3% per year (Maddams, 
eta!., 2009). The breast cancer population is no exception; due to improvements in cancer 
care, earlier diagnosis and treatment larger numbers of women are living longer and 
cancer-free after diagnosis and treatment. Many survivors, once having completed primary 
therapy (surgery, chemotherapy/biotherapy, and/or radiation) continue to have long-lasting 
symptoms, single or multiple (Barsevick, 2007; Cleeland, 2007; Janz, et al., 2007; Rosedale 
& Fu, 201 0). The experience of multiple symptoms has been identified as symptom burden 
(Burkett & Cleeland, 2007; Gapstur, 2007; Gill, Chakraborty & Selby, 2012). Symptom 
burden is defined as the subjective, quantifiable prevalence, frequency and severity of 
symptoms and encompasses the patient's perception of the impact of symptoms (Cleeland, 
2007; Gapstur, 2007). 
The experience of symptoms in survivors has been evaluated, but much of the I iterature has 
been focused on symptoms and suppmtive care during primary therapy (Chung, et al., 
2009). Some studies have concentrated on the early survivorship periods; beginning at the 
end of primary therapy up until27 months alter completing primary therapy (Janz, et al., 
2007, Thompson, 2007, Park, Bae, Jung & Kim, 2011, Penttinen, et al., 2010,, Brant, et al., 
2011, Yi, Swartz and Reyes-Gibby, 2011, Ganz, Kwan, Stanton, Bower and Belin, 2011). 
These studies have found symptoms related to primary therapy with an impaired quality of 
life related to these reported symptoms (Janz, et al., 2007, Park, et al., 201 L Bower, 2008, 
Dahl, Nesvold, Reinertsen, & fossa, 20 ll ). The symptoms most fi·equently cited in the 
aforementioned studies included pain, fatigue or lack of energy, difficulty sleeping, arm 
pain and lymphedema. breast symptoms, feeling irritable or nervous, menopausal 
symptoms, weight changes, nausea, depression, and cognitive dysfunction. A number of 
studies have focused on a specific symptom, such as pain (Mao, et al., 2009, Lundstedt, et 
a!., 2012, Rief, eta!., 2011), lymphedema (Armer & Stewart, 2010, Meeske, et al., 2009, 
Smoot, eta!. 20 10), fatigue (Bower, et al, 2008, Bower, eta!., 2011, Thompson, 2007) or 
menopausal symptoms (Leining, et al., 2006, Loibl, Lintermans, Dieudonne, & Neven, 
2011, Ruddy, eta!., 20 II). Cancer related fatigue was identified by 21% of both the 1-5 
year and 5-1 0 year survivors (Bower, et a!., 2008). Sleep disturbances, fatigue and pain 
persisted in Hartl eta!. 's study of survivors evaluated at an average of 4.2 years (2003). 
Several studies have had contradictory findings. Castellon, et al. found that cognitive 
dysfunction symptomatically abated in the 12-24 months after adjuvant chemotherapy 
(2004). Jim, et al., (2009) found significant differences between women who had received 
chemotherapy or radiation compared to healthy matched controls after 6 months. Tannock, 





patients, although the higher percentages were seen in those evaluated in a closer time 
frame with chemotherapy. However, in their study of longer term survivors (5 - 15 years), 
Klein eta!. (20 11) found an improvement in all symptoms except cognitive functioning and 
insomnia. The discrepancies among the findings may be related to the variability in primary 
therapy over time, pre-existing comorbidities or the use of adjuvant endocrine or hormonal 
therapy. 
Conceptual Framework Symptom Burden 
The proposed study will address the symptoms experienced by both early smvivors (less 
than 3 years after completion of primary therapy) and longer term survivors (years 3-5 after 
completion of primary therapy). Symptoms may be caused by comorbid illnesses or acute 
injuries, related to the disease itself or may be caused by treatments, in which case they are 
called side effects or toxicities (Cleeland, 2007). The framework of Symptom Burden 
(Cleeland, 2007, Gapstur, 2007) is the conceptual framework chosen for this study. 
Symptom burden has been described as the subjective counterpart to tumor burden 
(Cleeland & Reyes-Gibby, 2002) as well as the sum ofthe severity and impact of symptoms 
(Cleeland, 2007). It affects multiple patient outcomes, including survival, functional status 
and quality of life. (Gapstur, 2007). Symptom burden is active, and changes over time, as 
patients undergo treatment or experience exacerbations or remissions of their disease (Vig 
& Pearlman, 2003 ). In this framework, symptoms related to treatment often are viewed as 
compl icating post treatment recovery (Cleeland, 2007, Cleeland & Reyes-Gibby, 2002). 
In this study, we will assess functional status, comorbidities and the experience of symptom 
burden. This study also will explore the association of comorbidities and symptoms 
expressed by early and long term survivors. The evaluation of concunent co morbidities is 
wananted because as comorbidities have been related to symptom severity (Kurtz, et a!, 
1999). This study will also address the associations between functional status and 
symptoms related to adjuvant endocrine or hormonal therapy. 
Historically, the literature has addressed the symptoms of survivors during their primary 
therapy or shortly thereafter. But no studies have identified and compared the symptoms 
experienced by early and long term breast cancer survivors related to the use of adjuvant 
endocrine or hormonal therapy. 
2.0 Objectives 
Primary Objectives 
1. To determine whether symptom burden differs between early survivors (less than 
3 years post-primary treatment) and long-term survivors (3 to Jess than 6 years 
post -treatment, inclusive). 
2. To determine whether symptom burden differs between women who take 






1. To determine, whether the effect of time post-treatment and endocrine or 
hormonal adjuvant therapy has an additive effect upon symptom burden or 
whether it has a synergistic or antagonistic effect upon symptom burden. 
2. To determine whether symptom interference differs between early survivors and 
long-term survivors and between those who do and do not take adjuvant endocrine 
or hormonal therapy, as well as to determine if time post-treatment and use of 
adjuvant endocrine or hotmonal therapy have an additive or interactive effect 
upon symptom interference. 
3. To determine if differences in individual symptom severity and interference exist 
between early and long-term survivors, with and without the use of adjuvant 
endocrine or hormonal therapy. 
Exploratory Objective 
To determine whether functional status and comorbidities affect symptom severity and 
interference. 
3.0 Number of Patients 
We plan to enroll 33 early survivors who have not received adjuvant endocrine or hormonal 
therapy, 35 early survivors who have received (or are cunently receiving) adjuvant 
endocrine or hormonal therapy, 33 long-term survivors who have not received adjuvant 
endocrine or hormonal therapy, and 33 long-term survivors who have received (or are 
currently receiving) adjuvant endocrine or hormonal therapy. Early survivors are those who 
finished primary treatment less than 3 years prior to the date of survey; long term survivors 
are those who finished their primary treatment at least 3 years prior to date of survey but 
less than 6 years prior to the date of survey. 
We wi ll stratify the participants by stage so that 1/3 of each group will have had Stage I 
cancer, 1/3 will have had Stage II cancer and 1/3 will have had Stage III cancer. We expect 
that approximately 80% of breast cancer patients will have used adjuvant endocrine or 
honnonal therapy, and that the pool of early-term survivors will be larger than the pool of 
late-term survivors. Therefore, we will accrue each survivor type until we meet minimum 
sample size requirements for the group; this means that enrollment in some groups and 
strata of the study might stop before enrollment in other groups. This may lead to biased 
results since not all women will be enrolled from the same time cohort, however, this is a 
pilot study to be used to plan a longitudinal study and therefore these results will be for 
hypothesis generation when planning a future study. 
4.0 Patient Eligibility 
Inclusion criteria: 
Study participants must: 
I. Be a woman 18 years of age or older. 
2. Be a survivor with a diagnosis of invasive breast cancer who has no clinical 
evidence of disease. 
3. Have completed primary therapy (surgery, chemotherapy/biotherapy, and 
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radiation) less than six years prior to study entry. She may continue to receive 
adjuvant endocrine or hormonal therapy including tamoxifen, toremifene, 
anastrazole, exemestane or letrozole. 
4. May be non-English speaking. 
Exclusion criteria: 
1. Study participants may not be diagnosed with noninvasive, metastatic, 
inflammatory, or recutTent breast cancer. 
2. Participants may not be receiving chemotherapy or biotherapy at time of 
enrollment. 
3. Lack of approval of each participant's physician. Physician's will be approached 
by the investigator and asked if they feel the participant meets entry criteria prior 
to the subjects being approached for consideration of enrollment. 
4. Pregnant women will be excluded. 
5.0 Instruments 
MDASI-The MDASI will be used to measure symptom severity, interference and burden. 
The MD ASI is a 19-item self-report measure of the severity and impact of cancer-related 
symptoms (Cleeland et al, 2000). Respondents are asked to rate the severity of 
cancer-related symptoms (13 items) and their interference (6 items) with individual 
functioning. The global symptom severity and global interference scores measure the 
patient's symptom burden. Validity has been tested using principle factor analysis with 
oblique rotation; reliability established with alphas ranging from 0.82-0.85 for the symptom 
items and 0.91 for the interference scale (Cleeland, et al., 2000). The MDASI is available 
in multiple languages. 
The Karnofsky Performance Status (KPS)-The KPS will be used to measure functional 
status. The KPS is a clinician or investigator completed scale that classifies patients based 
on their degree of functional impairment on a scale from 0( dead) to 1 OO(normal, no 
complaints, no evidence of disease). (Schag, Heinrich and Ganz, 1984). It is further 
subgrouped into three groups: A. Able to carry on normal activity and to work, no special 
care needed, B. unable to work, able to live at home and care for most personal needs, 
varying amount of assistance needed and C. Unable to care for self, requires equivalent of 
institutional or hospital care; disease may be progressing rapidly. The KPS has shown 
reliability and validity previously with Cronbach's alpha of 0.97 and construct validity 






The Charlson Comorbidity Index (CCI) - The CCI will measure comorbidities. The CCI 
is an investigator completed index that measures 17 clinical conditions that are weighted to 
assess the effect of the conditions on the patient's prognosis. Item scores range from 1 to 6 
for each item and are based on the relative risk for each. Scores range from 0 to 34, with 
higher scores signifying greater comorbidity. An adjustment will be made to address all 
patiicipants beginning with a score of2, given because they all have cancer. It has 
established reliability with clinical conditions, including cancer (Hallet al., 2004). 
6.0 Data Collection Procedures 
Enrollment: The investigator will check with the Nellie B. Connelly Breast c.enter 
appointment desk for eligible patients based on inclusion criteria. Physicians will be 
contacted for permission to approach the patient. 
Data Collection Procedures: 
1. Review Breast Center appointment schedule for sunrivors less than 3 years after 
completion of primary therapy and those from 3 -5 years. 
2. Check with primary attending oncologist to ask if it would be permissible to 
approach the patients to seek their participation in a study on symptom 
assessment. 
3. Once the patient is in a clinic exam room, knock on the door, introduce self as a 
researcher and ask if this is a good time to speak with the patient. 
4. Explain the purpose of the study. The participant will complete a symptom instrument and 
either the participant or the investigator will complete the demographic history form. The 
expected time frame for completion is no more than 1 0-15 minutes. Ask if there any 
questions. 
5. Once all questions have been addressed to the patient's satisfaction, ask ifthey 
would agree to participate in the study. 
6. Provide the consent and wait for the signature before proceeding. 
7. Provide a copy of the demographic history form to the patient and ask them to 
complete it or the investigator will complete it. 
8. The investigator will determine the functional status of the patient (Karnofsky 
score); gather information from the medical record to complete the Charlson 
Co-morbidity Index. 
9. Provide a copy of the MDASI to the patient and explain the scoring. 
I 0. If the patient wishes to stop before completing the instrument, thank them for their 
time and exit the room. 
11. Ask the patient if they have any symptoms not listed on the MDASI to list them 
on the bottom of the MDASI. 
12. Note the time the instrument was started and time completed. 
13. Before placing the completed instruments in a plain unmarked envelope, review to 
check for missing data. If any data are missing, the investigator will review with 
the patient for an error in completing the instrument or a comprehension issue. 
14. Each envelope containing completed instruments and consents will be kept in a 





be assigned a study number. 
15. If the patient expresses distress, or rates any symptom 7 or higher, the researcher 
will contact their treating physician. The patient will also be instructed to contact 
their health care team. 
7.0 Evaluation During Study 
The primary researcher will track time from primary treatment and receipt of endocrine or 
honnonal therapy to ensure equitable distribution of participant populations. Descriptive 
data will be reviewed weekly to assess adequate representation of time since completion of 
primary therapy. The researcher will track estrogen or progesterone receptor status, as it 
may not be equitably distributed across different disease stages, in order to maintain a 
sample representative of each group. 
8.0 Data Monitoring Plan 
The investigator and dissertation chair will meet weekly to review progress. The primary 
investigator will review weekly to ensure adequate representation across stages and 
estrogen receptor status. Other committee members may attend as desired. All portions of 
the study being conducted, including any missing data, enrollment of subjects, adverse 
effects, data collection and protection strategies will be reviewed. This study is minimal 
risk, so study related adverse effects are not expected. Should any adverse effects occur, 
they will be investigated, logged, and reported to both the MD Anderson Cancer Center's 
IRB and the University of Texas Health Science Center (CPHS) within 48 hours of 
occurrence. This study is expected to be completed within one year. Progress of the study, a 
completed report, adverse event logs, certification oftraining requirements, HIPPA fonns, 
and publications resulting from this study will be sent to the IRB and CPHS at the 
completion of the study and during any audits. 
9.0 Protocol Monitoring Plan 
Security Plan: Paper instruments will be coded and de-identified. The code list will be 
kept in the PI's office in a locked cabinet and not shared. All completed instruments will 
be placed in a brown envelope upon completion and stored in a locked file with no 
identifiers. Once the information is transferred into the computer, the file will be 
password protected. Once the study is completed, all paper data including the code list 
will be shredded. 
Distress Plan: If the patient expresses distress, or rates any symptom 7 or higher, the 
researcher will contact their treating physician. The patient will also be instructed to 






Using a 2x2 factorial design, we will have 80% power to detect a one-unit difference in 
mean symptom burden scores by use of adjuvant endocrine or hormonal therapy, which 
translates to a standard deviation among means of0.5. Additionally, we have over 95% 
power to detect a 2-unit difference between early-term and long-term survivors, which is 
the same as a I .0 standard deviation among means, and to detect a 1.12 standard deviation 
among means for the interaction effect. All testing will be 2-sided using a 5% level of 
statistical significance. A subject standard deviation of2.0 was used to calculate power, 
based upon findings by Cleeland, et. al. (2000). Because we have two primary objectives, 
we will have a 10% chance of falsely rejecting at least one of our primary hypotheses. 
Descriptive statistics will be used to assess the distributional characteristics and 
demographics of the study sample. Summary statistics and graphs will be used to examine 
symptom burden, as well as individual symptom severity and interference. Fisher's exact 
tests and t-tests will be used to determine whether demographic and clinical baseline data 
are similar between short- and long-term survivors, as well as between those who had 
adjuvant endocrine or hormonal therapy and those who did not. Symptom burden and 
interference will be calculated separately, as recommended by the MDASI User Guide. We 
will use 2-way ANOV A models to evaluate differences in symptom burden, symptom 
interference and severity/interference of individual symptoms. Finally, we will add 
Karnofsky Performance Status and the Charlson Comorbidity Index to our models to 
evaluate impact of functional status and comorbidities upon symptoms. All models will 
contain terms for stage of disease to account for stratification on that factor, as well as a 
term for age to adjust for the effects of age upon symptom severity and interference. 
Anticipated Problems and Alternate Strategies 
Missing data: A single investigator will be collecting the data. The completed forms will 
be reviewed when collected. Any missing data will be discussed to ascertain an error in 
completing the instrument or a comprehension difficulty with an item. Percent of missing 
items will be calculated and is expected to be less than 1%. The MDASI User's Guide 
allows for calculation of severity and interference scores when not all items are answered. 
Its recommendations will be implemented when not all 19 items are answered. 
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IviD Anderson 
-Gm~r Ce11ter 
Specialized Informed Consent 
INFORMED CONSENT/AUTHORIZATION FOR PARTICIPATION IN 
RESEARCH 
Symptoms in Early and Long-term Breast Cancer Survivors Who Have 
Completed Primary Therapy 
2012-0909 
Subtitle: 
Study Chair: Faith A. Strunk 
1. 
Participant's Name Medical Record Number 
You are being asked to take part in this psychosocial research study at The 
University of Texas MD Anderson Cancer Center ("MD Anderson"). This consent 
form explains why this research study is being done and what your role will be if you 
choose to take part. This form also describes the possible risks connected with 
being in this study. After reviewing this information with the person responsible for 
your enrollment, you should know enough to be able to make an informed decision 
on whether you want to take part in the study. 
You are being asked to take part in this study because you are a woman who has 
been treated for breast cancer and are receiving follow up care. 
DESCRIPTION OF RESEARCH 
2. PURPOSE OF STUDY 
The goal of this research study is to learn what symptoms breast cancer survivors 
may be having after completing primary therapy (surgery, chemotherapy or 
biotherapy, and/or radiation). Researchers also want to learn how taking tamoxifen, 
NOT FOR USE IN CONSENTING PATIENTS 
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anastrazole, letrozole, or exemestane impacts the activities of daily living, time after 
primary therapy, and chronic illnesses. 
3. DESCRIPTION OF STUDY 
If you agree to take part in the study, you will complete a questionnaire about any 
symptoms you may be having after primary therapy. You will also complete a 
questionnaire that asks about your background such as age, employment, and any 
chronic illnesses that you may have. 
The questionnaires should take a total of about 20 minutes to complete. If your 
questionnaires suggest that you are depressed, upset, or distressed, the researcher 
will let your clinic team know. 
Length of Study 
Your participation in this study will be over after you complete the second 
questionnaire. 
This is an investigational study. There will be no cost to you for participating in 
this study. 
Up to 135 participants will be enrolled in this study. All will take part at MD 
Anderson. 
4. RISKS, SIDE EFFECTS, AND DISCOMFORTS TO PARTICIPANTS 
You should discuss the risks of questionnaires with the study chair. The known 
risks are listed in this form, but they will vary from person to person. Some 
questions may make you feel upset or uncomfortable. You may refuse to answer 
any question. If you have concerns after completing the questionnaires, you are 
encouraged to contact the study researchers or staff. 
Although every effort will be made to keep study data safe, there is a chance that 
your personal health information could be lost or stolen. All study data be stored in 
password-protected computers and/or locked file cabinets. There will be no 
personal identifying information connected to your questionnaire answers. The 
study data will be destroyed 5 years after the study has been published. 
Researchers will take appropriate steps to keep your information private. However, 
there is no guarantee of absolute privacy. 
This study may involve unpredictable risks to the participants. 
NOT FOR USE IN CONSENTING PATIENTS 
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Future patients may benefit from what is learned. There are no benefits for you in 
this study. 
6. ALTERNATE PROCEDURES OR TREATMENTS 
You may choose not to take part in this study. You may seek help for any 
symptoms you may be having outside of this study by seeing your doctor. 
NOT FOR USE IN CONSENTING PATIENTS 
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Additional Information 
7. You may ask the study chair any questions you have about this study. You may 
contact the study chair, Faith A. Strunk, at 713-563-0774. You may also contact 
the Chair of MD Anderson's Institutional Review Board (IRB - a committee that 
reviews research studies) at 713-792-2933 with any questions that have to do with 
this study or your rights as a study participant. 
8. Your participation in this research study is strictly voluntary. You may choose not to 
take part in this study without any penalty or loss of benefits to which you are 
otherwise entitled. You may also withdraw from participation in this study at any 
time without any penalty or loss of benefits. If you withdraw from the study, data 
collected about you up to the time you withdrew may have to remain in the study 
database for inclusion in the data analysis. If you decide you want to stop taking 
part in the study, it is recommended for your safety that you first talk to your doctor. 
If you withdraw from this study, you can still choose to be treated at MD Anderson. 
9. This study or your participation in it may be changed or stopped at any time by the 
study chair or the IRB of MD Anderson. 
10. You will be informed of any new findings that might affect your willingness to 
continue taking part in the study. 
11. MD Anderson will take appropriate steps to keep your personal health information 
private. However, there is no guarantee of absolute privacy. Health authorities, 
and the IRB of MD Anderson might review your record to collect data or to check 
that the research is being done safely and correctly. In some situations, health 
authorities could be required to reveal the names of participants. 
12. MD Anderson may benefit from your participation and/or what is learned in this 
study. 
STUDY COSTS AND COMPENSATION 
If you suffer injury as a direct result of taking part in this study, MD Anderson health 
providers will provide medical care. However, this medical care will be billed to your 
insurance provider or you in the ordinary manner. You will not be reimbursed for 
expenses or compensated financially by MD Anderson for this injury. You may also 
contact the Chair of MD Anderson's IRB at 713-792-2933 with questions about 
study-related injuries. By signing this consent form, you are not giving up any of your 
legal rights. 
Unless otherwise stated in this consent form, all of the costs linked with this study, 
which are not covered by other payers (health maintenance organization [HMO], 
health insurance company, etc.), will be your responsibil ity. 
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There are no plans to compensate you for any patents or discoveries that may result 
from your participation in this research. 
You will receive no compensation for taking part in this study. 
Authorization for Use and Disclosure of Protected Health Information: 
A. During the course of this study, the research team at MD Anderson will be 
collecting information about you that they may share with the parties named in 
Section E below. 
B. If you refuse to provide authorization to disclose your protected health 
information, you will not be able to participate in this research study. 
C. Your protected health information will be protected according to state and federal 
law. However, there is no guarantee that your information will remain 
confidential, and it may be re-disclosed at some point. 
D. All identifying information such as your name and address will be kept private. 
This information may be kept at MD Anderson forever. You will be assigned a 
code number so that your name will not be used. The research team at MD 
Anderson will be able to link the code number to your name. In some instances, 
in order to ensure the scientific value of the study, the parties named in Section 
E below will be able to view your study record but will not be permitted to copy 
any identifying information contained in your record. 
E. The following parties may view your identifying information: 
• Officials of the doctoral nursing program at the University of Texas -Houston 
Health Science Center School of Nursing 
• The Office for Human Research Protections (OHRP) (a regulatory agency 
that oversees research in humans) 
• The IRB of MD Anderson 
• Officials of MD Anderson 
• Study monitors who verify the accuracy of the information 
• Individuals who put all the study information together in report form 
F. You have the right to see and reproduce your records related to the research study, 
and ask for corrections, for as long as this information is held by the study chair 
and/or MD Anderson. However, in some studies, in order to ensure the scientific 
value of the study, participants are not able to view or reproduce their study records 
until the research has been completed with all participants in the study. 
G. There is no expiration date for the use of your information as stated in this 
authorization. You may withdraw your authorization to share your protected health 
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information at any time in writing. Instructions on how to do this can be found in the 
MD Anderson Notice of Privacy Practices (NPP). You may contact the IRB Staff at 
713-792-2933 with questions about how to find the NPP. If you withdraw your 
authorization, you will be removed from the study, and the study chair and staff will 
no longer use or disclose your protected health information in connection with this 
study, unless the study chair or staff needs to use or disclose some of your 
research-related personal health information to preserve the scientific value of the 
study. The parties listed in Section E above may use any study data that were 
collected before you canceled your authorization. 
H. A description of this clinical trial will be available on http://www.CiinicaiTrials.gov, 
as ·required by U.S. Law. This Web site will not include information that can 
identify you. At most, the Web site will include a summary of the results. You 
can search this Web site at any time. 
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I understand the study. I have had a chance to read the consent form for this study, or 
have had it read to me. I have had a chance to think about it, ask questions, and talk 
about it with others as needed. I give the study chair permission to enroll me on this 
study. By signing this consent form, I am not giving up any of my legal rights. I will be 
given a signed copy of this consent document. 
SIGNATURE OF PARTICIPANT DATE 
LEGALLY AUTHORIZED REPRESENTATIVE {LAR) 
The following signature line should only be filled out when the participant consents to 
take part in the study but does not have the capacity to legally sign this document on 
his or her own behalf. 
SIGNATURE OF LAR DATE 
WITNESS TO CONSENT 
I was present during the explanation of the research to be performed under Protocol 
2012-0909. 
SIGNATURE OF WITNESS TO THE VERBAL CONSENT PRESENTATION DATE 
(OTHER THAN PHYSICIAN OR STUDY CHAIR) 
A witness signature is only required for vulnerable adult participants. If witnessing the assent of a pediatric 
participant, leave this line blank and sign on the witness to assent page instead. 
PERSON OBTAINING CONSENT 
I have discussed this psychosocial research study with the participant and/or his or her 
authorized representative, using language that is understandable and appropriate. I 
believe that I have fully informed this participant of the nature of this study and its 
possible benefits and risks and that the participant understood this explanation. 
SIGNATURE OF STUDY CHAIR DATE 
OR PERSON AUTHORIZED TO OBTAIN CONSENT 
NOT FOR USE IN CONSENTING PATIENTS 
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TRANSLATOR 
I have translated the above informed consent as written (without additions or 
subtractions) into and assisted the people 
(Name of Language) 
obtaining and providing consent by translating all questions and responses during 
the consent process for this participant. 
NAME OF TRANSLATOR SIGNATURE OF TRANSLATOR DATE 
0 Please check here if the translator was a member of the research team. (If 
checked, a witness, other than the translator, must sign the witness line below.) 
SIGNATURE OF WITNESS TO THE VERBAL TRANSLATION DATE 
(OTHER THAN TRANSLATOR, PARENT/GUARDIAN, OR STUDY CHAIR) 







Faith A. Strunk 
6901 Bertner Avenue, #606, Houston TX 77030 
713-500-2186/713-500-2171 fax 
faith.a.strunk@uth.tmc.edu 
University of Texas Health Science Center 
At Houston 
School of Nursing 
6901 Bertner Avenue 
Houston, TX 77030 
University of North Carolina 
105 Hanes Hall CB 2100 
Chapel Hill, NC 27599-2100 
BS, Comp Studies: Info Sys Mgmt University of Maryland-European Division 
University Blvd at Adelphi Road 
BSN 
LICENSURE & CERTIFICATION 
RN No. 
College Park, MD 20742 
Arizona State University 
PO Box 870312 
Tempe, AZ 85287-0312 
State 
RN, Family Nurse Practitioner 650215 Texas 
Certificate Certifying Body 
Family Nurse Practitioner American Nurses Credentialing Center 
Advanced Oncology Certified Nurse Oncology Nursing Certification Corporation 
Practitioner 
PROFESSIONAL EXPERIENCE 
Institution Position title 
Various military hospitals Clinical Staff Nurse 
Acute Minor Illness Clinic, Ft. Myer, Head Nurse 
VA 


















1151h Field Hospital, Ft. Polk, LA 
McNeese State University, Lake 
Charles, LA 
Rural Health Clinic, LaGrange, GA 
UTMB Correctional Managed Care 
CT Terrell Unit 
1300 FM 655 
Rosharon, TX 77583 
Assistant Chief Nurse 
Adjunct Faculty 
Manager, Family Nurse Practitioner, & Diabetes 
Educator 
Midlevel provider (Family Nurse Practitioner) 
UTMB Regional Maternal Child Health Family Nurse Practitioner 
Program 
1108 E. Mulberry St. Suite A 
Angleton, TX 77515 
UTMB Correctional Managed Care 
CT Terrell Unit 
1300 FM 655 
Rosharon, TX 77583 
Family Nurse Practitioner 
University of Texas M. D. Anderson Advanced Practice Nurse 
Cancer Center 
Department of Breast Medical 
Oncology 
1515 Holcombe Blvd Unit 1354 
Houston, TX 77030 
INTERNATIONAL EXPERIENCE 
Institution 




M . D. Anderson Scholar for the University of Texas M. D. Anderson Cancer 
University of Texas School of Nursing Center 

















Other Funded Projects Including Contracts for Service 
None 
PUBLICATIONS 
Peer Reviewed Publications 
None 
Non-Peer Reviewed Publications 
Strunk, F. A. {1997). My day at the capital, Georgia Nursing, 57(2): 3. 
Books & Chapters 
None 
Media & Other Creative Products 
None 





Strunk, F. {10/2008)- Survivorship Issues and Strategies to Meet the Needs of Survivors, Chilean 





09/06- Breast Cancer: Risk Factors, New Treatment Options, and Symptom Management, Nurse 
Oncology Education Program, Laredo, Texas, speaker, invited 
02/07- Breast Cancer: Risk Factors, New Treatment Options, and Symptom Management, Nurse 
Oncology Education Program, Harlingen, Texas, speaker, invited 
03/07- Breast Cancer: Risk Factors, New Treatment Options, and Symptom Management, Nurse 
Oncology Education Program, Beaumont, Texas, speaker, invited 
12/08- Breast Canc·er: Risk Factors and Breast Cancer: New Treatment Options and Symptom 
Management. Women's Health Update, Nurse Oncology Education Program, Austin, TX, 
speaker, invited 
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03/09- Breast Cancer: Risk Factors and Breast Cancer: New Treatment Options and Symptom 
Management. Women's Health Update, Nurse Oncology Education Program, Bryan, TX, speaker, 
invited 
12/10 -- Breast Cancer ... What Do I Do When My Breast Cancer Patient Has This?, Care of the Cancer 
Patient, Nurse Oncology Education Program, Temple, Texas, speaker, invited 
03/11- Breast Cancer Double Check, SPARC program, Nurse Oncology Education Program, McAllen, 
Texas, speaker, invited 
03/11 --Breast Cancer, Well Women: Breast and Cervical Health, Nurse Oncology Education Program, 
Abilene, Texas, speaker, invited 
04/11- Breast Cancer, Well Women: Breast and Cervical Health, Nurse Oncology Education Program, 
Tyler, Texas, speaker, invited 
05/12- Breast Cancer: Risk Factors, Evaluation, and Treatment Options, Faculty Training Program, Nurse 
Oncology Education Program, Houston, Texas, speaker, invited 
12/12 --Update on Breast Cancer Treatment 2012, 2012 Texas Department of State Health Services 
Clinical Conference, Cardea, Austin, TX, speaker, invited 
10/13- The Joining Forces Initiative, Service Learning Opportunities and Nursing Students: An 
Innovative Program, Joining Forces to Restore Lives: Nursing Education and Research in 
Veterans Health, Tampa, FL, speaker, invited 
05/11 -- Breast Cancer, Faculty Training Program, Nurse Oncology Education Program, Houston, Texas 
04/05-04/10 --Breast Cancer; Cancer Care Course: Solid Tumor Day 1, quarterly lecture, Nursing 
Professional Development & Education, M. D. Anderson Cancer Center; Houston, Texas 
05/05- Breast Cancer, Faculty Training Program, Nurse Oncology Education Program, Houston, Texas 
04/06- Breast Cancer Update, Advanced Practice Nurses General Meeting, M.D. Anderson Cancer 
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Oncology Nursing Society, member 
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Texas Nurse Practitioners, member 
Institutional Service 
Institution Committee 
M. D. Anderson Cancer Center APN Orientation Committee 
M. D. Anderson Cancer Center APN Leadership Committee 
M. D. Anderson Cancer Center APN Practice/Competency 
University of Texas HSC 
School of Nursing 
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Sacred Heart Co-Cathedrat Houston, TX various ministries Leader 
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